All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000012-13 | A Double-Blind, Placebo-Controlled, Parallel, Randomized Study To Evaluate The Efficacy And Safety Of 3 Oral Dose Levels Of TMI-005 In Subjects With Active Rheumatoid Arthritis On A Background Of Meth... | 2005-08-31 | due-trials |
| Reported results | 2004-000015-25 | A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women with ... | 2006-09-25 | due-trials |
| Ongoing | 2004-000016-10 | A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF SRA-333 IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH DON... | not-yet-due | |
| Reported results | 2004-000035-28 | TDS-943 MAXIMUM USE TOLERANCE STUDY | 2004-12-01 | due-trials |
| Reported results | 2004-000139-27 | A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally, ... | 2006-07-31 | due-trials |
| Reported results | 2004-000156-16 | Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on ... | 2007-04-29 | due-trials |
| Reported results | 2004-000219-24 | A multicenter study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital hemophilia A who develop de novo factor VIII inhibitors while receiving factor ... | 2007-11-08 | due-trials |
| Reported results | 2004-000244-24 | A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. | 2005-06-03 | due-trials |
| Reported results | 2004-000354-22 | An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study) | 2006-09-19 | due-trials |
| Completed, but no date, and reported results | 2004-000363-10 | A Randomized Open Label Study to compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in de novo Renal Allograft Recipients | bad-data | |
| Reported results | 2004-000365-35 | Prospective, Open-label, Non-comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) with Voriconazole in Patients with Allogeneic Stem Cell Transplants | 2008-04-04 | due-trials |
| Reported results | 2004-000397-31 | A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administr... | 2006-12-11 | due-trials |
| Completed, but no date, and reported results | 2004-000450-23 | A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | bad-data | |
| Completed, but no date, and reported results | 2004-000562-13 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER | bad-data | |
| Reported results | 2004-000563-96 | A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHEUMA... | 2008-06-25 | due-trials |
| Reported results | 2004-000622-67 | A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy. | 2007-01-31 | due-trials |
| Reported results | 2004-000827-13 | LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | 2010-07-08 | due-trials |
| Reported results | 2004-000935-27 | A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipient... | 2008-08-23 | due-trials |
| Completed, but no date, and reported results | 2004-000954-22 | A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders | bad-data | |
| Completed, but no date, and reported results | 2004-000955-40 | A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder | bad-data | |
| Completed, but no date, and reported results | 2004-000971-33 | Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluation... | bad-data | |
| Reported results | 2004-000973-69 | A RANDOMIZED, OPEN-LABEL, COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF SIROLIMUS VERSUS CYCLOSPORINE WHEN COMBINED IN A REGIMEN CONTAINING BASILIXIMAB, MYCOPHENOLATE MOFETIL, AND CORTICOSTEROI... | 2006-06-28 | due-trials |
| Reported results | 2004-000996-33 | A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC). | 2005-10-07 | due-trials |
| Reported results | 2004-001093-11 | A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol | 2011-12-13 | due-trials |
| Reported results | 2004-001149-14 | A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma | 2008-09-19 | due-trials |
| Reported results | 2004-001190-25 | A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R... | 2006-03-12 | due-trials |
| Reported results | 2004-001200-12 | LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | 2007-07-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2004-001234-17 | Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje... | 2009-05-11 | bad-data |
| Reported results | 2004-001258-94 | A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin Exubera on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poor... | 2007-05-11 | due-trials |
| Completed, but no date, and reported results | 2004-001301-10 | A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL... | bad-data | |
| Completed, but no date | 2004-001321-25 | A prospective, open label, monocenter trial to evaluate the interaction between the Platelia Aspergillus ELISA test and the administration of piperacillin/tazobactam. | bad-data | |
| Completed, but no date, and reported results | 2004-001378-19 | A two part study to a) investigate the reproducilibility of the vaginal photoplethysmograhpy (VPP) teqnique in healthy pre-menopausal volunteers and subjects suffering from Female Sexual Arousal Disor... | bad-data | |
| Completed, but no date, and reported results | 2004-001379-20 | A two part study to a) investigate the reproducibility of the vaginal photoplethysmography (VPP) technique in healthy post-menopausal volunteers and subjects suffering from Female Sexual Arousal Disor... | bad-data | |
| Reported results | 2004-001430-16 | An Open-Label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CCI-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (... | 2011-01-04 | due-trials |
| Reported results | 2004-001467-22 | A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER | 2007-03-19 | due-trials |
| Completed, but no date, and reported results | 2004-001497-13 | A RANDOMIZED, OPEN LABEL, TRIAL OF THE PHARMACOKINETICS OF AZITHROMYCIN IN SERUM, BRONCHIAL WASHINGS AND LUNG TISSUE FOLLOWING A SINGLE DOSE OF NEW FORMULATION AZITHROMYCIN MICROSPHERES (2 GRAM) OR CO... | bad-data | |
| Reported results | 2004-001500-13 | An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalize... | 2006-11-30 | due-trials |
| Completed, but no date, and reported results | 2004-001511-54 | Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections. | bad-data | |
| Reported results | 2004-001557-29 | A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS... | 2009-05-12 | due-trials |
| Reported results | 2004-001559-12 | Measurement of Urethral Function in Women with Stress Urinary Incontinence - Evaluation of the Sensitivity of Urethral Reflectometry compared to Urethral Pressure Profilometry, using [S,S]-Reboxetine ... | 2006-06-07 | due-trials |
| Reported results | 2004-001586-18 | A Safety Study of TDS-943 | 2005-05-19 | due-trials |
| Reported results | 2004-001607-35 | AN OPEN-LABEL, MULTICENTER STUDY WITH FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE IN COMPARISON TO TRANSDERMAL NICOTINE PATCH FOR SMOKING CESSATION | 2006-06-28 | due-trials |
| Reported results | 2004-001637-41 | A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® (Paracetamol (500mg)/Pseudoephedrine (30mg)) on subjects with nasal congestion accompanied by head... | 2008-03-25 | due-trials |
| Reported results Terminated | 2004-001713-34 | RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE ... | 2005-03-01 | due-trials |
| Reported results | 2004-001778-21 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F... | 2011-04-19 | due-trials |
| Reported results | 2004-001779-20 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR... | 2009-04-07 | due-trials |
| Reported results | 2004-001860-27 | A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE | 2011-10-05 | due-trials |
| Reported results | 2004-001914-15 | A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi... | 2012-12-13 | due-trials |
| Reported results | 2004-001955-12 | A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release form... | 2005-06-24 | due-trials |
| Reported results | 2004-002007-33 | An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibito... | 2007-07-11 | due-trials |
| Reported results | 2004-002215-80 | A Double-Blind, Parallel, Randomized Extension Trial to Evaluate Safety and Efficacy of TMI-005 (Apratastat) in Subjects with Rheumatoid Arthritis on Methotrexate Who Have Completed Protocol 3140A1-20... | 2013-01-01 | due-trials |
| Reported results | 2004-002216-28 | A multi-center, multinational, randomized, double-blind, placebo-controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 Modified Release on exercise capacit... | 2005-12-15 | due-trials |
| Reported results | 2004-002560-17 | A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophre... | 2007-08-02 | due-trials |
| Reported results | 2004-002563-24 | A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE TIME TO ONSET OF MEANINGFUL PAIN RELIEF IN SUBJECTS WITH POSTHERPETIC NEURALGIA (PHN) TREATED WITH PREGABALIN (150 - 600 MG/DAY FLEXIBLE OP... | 2006-06-28 | due-trials |
| Reported results | 2004-002629-36 | A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis | 2007-02-12 | due-trials |
| Completed, but no date, and reported results | 2004-002640-97 | Time to onset of action of tolterodine using force fill cystometry in SPINAL CORD INJURY PATIENTS WITH neurogenic detrusor overactivity. | bad-data | |
| Listed as ongoing, but also has a completion date | 2004-002648-88 | In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) | 2010-01-06 | bad-data |
| Reported results | 2004-002846-36 | A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN... | 2006-06-23 | due-trials |
| Reported results | 2004-002948-10 | A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH NEUROPATHIC PAIN ASSOCIATED WITH LUMBO-SACRAL RADICULOPATHY | 2007-06-19 | due-trials |
| Trial is outside EEC, and reported results | 2004-002991-40 | Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study | bad-data | |
| Trial is outside EEC, and reported results | 2004-002992-17 | EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM® | bad-data | |
| Exempt, with results | 2004-003016-30 | PHARMACOKINETICS OF NICOTINE FILM FOR USE IN THE MOUTH. A RANDOMIZED, CROSSOVER, PHASE-I, COMPARATIVE STUDY IN HEALTHY SMOKERS. | not-yet-due | |
| Completed, but no date, and reported results | 2004-003340-22 | A randomised, placebo controlled, double blind trial of asenapine in the prevention of relapse after long term treatment of schizophrenia. | bad-data | |
| Reported results | 2004-003727-12 | A Single Dose, Randomized, 2-Period Crossover Study in Patients with Hemophilia A to Evaluate the Pharmacokinetics of Refacto(B-domain deleted recombinant human factor VIII (BDDrFVIII) and Advate (a f... | 2005-11-23 | due-trials |
| Reported results | 2004-003737-13 | A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation. | 2006-09-28 | due-trials |
| Reported results | 2004-003778-27 | A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma | 2006-07-10 | due-trials |
| Reported results | 2004-003813-18 | A continuation study of CPG 7909 Injection in patients with matastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy | 2007-06-14 | due-trials |
| Reported results | 2004-004150-51 | A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation. | 2005-07-28 | due-trials |
| Reported results | 2004-004201-18 | A multicenter, open-label, randomized, pilot study to evaluate the efficacy and safety of the combination of etanercept (ETN) and methotrexate and of etanercept (ETN) alone in patients with active pla... | 2006-12-28 | due-trials |
| Exempt, with results | 2004-004232-31 | A double-blind (third party open), placebo-controlled, parallel group, multiple dose study to investigate the safety, toleration and pharmacokinetics of [S,S]-Reboxetine in young and elderly healthy v... | 2005-03-29 | not-yet-due |
| Reported results | 2004-004269-14 | Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once dai... | 2006-03-03 | due-trials |
| Completed, but no date, and reported results | 2004-004575-11 | PERCEPTION AND TOLERABILITY OF NICOTINE FILMS FOR USE IN THE MOUTH. A RANDOMIZED, CROSSOVER, PHASE-II, STUDY IN HEALTHY SMOKERS. | bad-data | |
| Reported results | 2004-004781-33 | Somatropin Therapy for Short Children Born of Premature Gestation: A Controlled, Prospective Randomized, Multicenter Study with an Untreated Control Group | 2010-03-24 | due-trials |
| Reported results | 2004-004837-33 | A randomised, double-blind, parallel group trial to assess the variability and treatment effect size for a Neuropathic Pain offset design | 2005-10-05 | due-trials |
| Exempt, with results Terminated | 2004-004857-24 | A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated w... | 2006-06-13 | not-yet-due |
| Reported results | 2004-004867-31 | A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen®... | 2008-03-31 | due-trials |
| Reported results | 2004-004918-17 | A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy | 2006-07-17 | due-trials |
| Reported results | 2004-005022-45 | A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause | 2006-02-08 | due-trials |
| Reported results | 2004-005159-32 | LINEZOLID VS VANCOMYCIN/CEFAZOLIN IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH CATHETER-RELATED GRAM-POSITIVE BLOODSTREAM INFECTIONS. | 2007-04-06 | due-trials |
| Reported results | 2004-005173-27 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISORDE... | 2007-12-05 | due-trials |
| Reported results | 2005-000051-15 | CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS ACCESSO CONTINUO ALL'INIBITORE DELLA TIROSIN-CHINASI D... | 2023-08-14 | due-trials |
| Reported results | 2005-000053-30 | A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION | 2008-03-17 | due-trials |
| Completed, but no date | 2005-000171-18 | A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3... | bad-data | |
| Reported results | 2005-000360-45 | A MULTICENTER, PARALLEL GROUP FLEXIBLE DOSE STUDY WITH A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED PHASE AND AN OPEN-LABEL PHASE TO EVALUATE THE QUALITY OF ERECTIONS IN MEN WITH ERECTILE DYSFUNCT... | 2006-01-31 | due-trials |
| Reported results | 2005-000448-99 | A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection | 2008-09-03 | due-trials |
| Reported results | 2005-000524-16 | AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH ADVANCED / METASTATIC GASTRIC CANCER PROGRESSING OR RECURRING AFTER ONE PRIOR CHEMOTHERAPY | 2008-06-10 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-000525-30 | AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA | bad-data | |
| Exempt, with results | 2005-000526-23 | A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER | 2008-09-15 | not-yet-due |
| Reported results Terminated | 2005-000639-13 | An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a sin... | 2006-05-30 | due-trials |
| Reported results | 2005-000671-17 | A Safety and Efficacy Dose-Ranging Study of GAP-486 in Subjects With Nonsustained Ventricular Tachycardia and Acute Ischemia | 2006-10-16 | due-trials |
| Reported results | 2005-000720-16 | A Randomised, Two-way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII Pr... | 2006-11-17 | due-trials |
| Exempt, with results | 2005-000917-37 | Comparision of single-dose nicotine pharmacokinetics of three variants of nicotine oral drops 2 mg and of Nicorette Gum 2 mg in healthy smokers | not-yet-due | |
| Ongoing | 2005-000936-26 | Sirolimus en el tratamiento de la nefropatía crónica del injerto demostrada histológicamente | not-yet-due | |
| Trial is partly outside EEC, and reported results | 2005-000963-25 | A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil in the Treatment of Subjects Who Have Completed Study A1481131 | 2012-12-24 | bad-data |
| Reported results | 2005-001040-23 | AN EVALUATOR-BLINDED, OPEN, RANDOMIZED, PARALLEL CONTROLLED STUDY ON NICORETTE® FRESHMINT GUM VS NICORETTE® MICROTAB IN HEALTHY SMOKERS MOTIVATED TO QUIT SMOKING AND WITH VISIBLE STAINING OF TEETH | 2005-11-10 | due-trials |
| Reported results | 2005-001128-35 | A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix... | 2006-07-25 | due-trials |
| Exempt, with results | 2005-001224-36 | Phase 1, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-751,871 in Patients with Advanced Solid Tumours | 2012-10-26 | not-yet-due |
| Reported results | 2005-001270-27 | A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA | 2008-05-15 | due-trials |
| Reported results | 2005-001303-19 | A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH ADVANCED GASTRO INTESTINAL STROMAL TUMOR | 2008-04-10 | due-trials |
| Reported results | 2005-001319-23 | A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Ther... | 2006-10-19 | due-trials |
| Reported results | 2005-001460-32 | A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00... | 2011-07-15 | due-trials |
| Reported results | 2005-001475-35 | A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S D... | 2007-06-01 | due-trials |
| Reported results | 2005-001476-13 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN SRA-333 SR IN PATIENTS WITH MILD TO MODERATE... | 2008-03-18 | due-trials |
| Reported results | 2005-001477-94 | A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DI... | 2007-11-22 | due-trials |
| Reported results | 2005-001478-28 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN SRA-333 SR IN PATIENTS WITH MILD TO MODERATE... | 2008-06-11 | due-trials |
| Reported results | 2005-001533-15 | A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis | 2008-03-29 | due-trials |
| Reported results | 2005-001549-41 | A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis | 2008-02-01 | due-trials |
| Reported results | 2005-001579-37 | An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery | 2008-06-12 | due-trials |
| Completed, but no date, and reported results | 2005-001658-25 | An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone def... | bad-data | |
| Reported results | 2005-002097-30 | A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO... | 2011-11-29 | due-trials |
| Reported results | 2005-002169-35 | A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 | 2008-01-16 | due-trials |
| Exempt, with results | 2005-002249-38 | A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE A... | not-yet-due | |
| Reported results | 2005-002411-25 | A prospective multicenter, parallel group study with a single blind phase and a double blind randomised phase, to evaluate the efficacy and satisfaction of Viagra® (Sildenafil Citrate) high dose (100m... | 2006-07-07 | due-trials |
| Reported results | 2005-002717-21 | A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC... | 2011-12-14 | due-trials |
| Reported results | 2005-002800-40 | Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet... | 2009-02-10 | due-trials |
| Reported results | 2005-002826-70 | A PHASE 2, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TICILIMUMAB IN PATIENTS WITH ADVANCED REFRACTORY AND/OR RELAPSED MELANOMA STUDIO DI FA... | 2010-02-19 | due-trials |
| Reported results | 2005-002827-15 | A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI... | 2010-08-20 | due-trials |
| Reported results | 2005-003006-29 | A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure | 2006-10-27 | due-trials |
| Reported results | 2005-003048-78 | A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain | 2008-05-27 | due-trials |
| Reported results | 2005-003097-19 | A Phase 2 Study of HKI-272 in Subjects with Advanced Non-Small Cell Lung Cancer | 2009-01-14 | due-trials |
| Reported results | 2005-003098-26 | Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer | 2018-04-20 | due-trials |
| Completed, but no date Terminated | 2005-003146-33 | INDIVIDUALIZED DOSE OF GENOTROPIN® (SOMATROPIN) TO SHORT PREPUBERTAL CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA): COMPARISON WITH FIXED DOSE TREATMENT IN EVALUATION OF GROWTH AND SAFETY IN AN OPEN, ... | bad-data | |
| Reported results | 2005-003290-25 | A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience including ... | 2006-09-01 | due-trials |
| Reported results | 2005-003351-12 | THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF) | 2012-01-24 | due-trials |
| Reported results | 2005-003501-90 | Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer | 2007-07-11 | due-trials |
| Reported results | 2005-003504-11 | A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on t... | 2008-02-19 | due-trials |
| Reported results | 2005-003713-32 | A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Chron... | 2006-09-01 | due-trials |
| Reported results | 2005-003773-25 | A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCER | 2010-07-20 | due-trials |
| Reported results | 2005-003774-15 | A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS... | 2011-04-26 | due-trials |
| Reported results | 2005-004023-19 | A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES | 2010-04-09 | due-trials |
| Reported results | 2005-004120-39 | A randomised, double blind, placebo-controlled, multicentre study in asymptomatic HIV infected patients to investigate pharmacodynamics, pharmacokinetics, safety and toleration of UK-453,061 | 2007-02-19 | due-trials |
| Reported results | 2005-004155-35 | A randomized, double blind, parallel group study to examine the effect of multiple doses of CJ-040,714 on distal esophageal acid exposure an patients with erosive gastro-esophageal reflux disease (GER... | 2007-01-20 | due-trials |
| Reported results | 2005-004167-27 | A PHASE 3, RANDOMIZED, 6-MONTH, DOUBLE BLIND TRIAL IN SUBJECTS WITH BIPOLAR I DISORDER TO EVALUATE THE CONTINUED SAFETY AND MAINTENANCE OF EFFECT OF ZIPRASIDONE PLUS A MOOD STABILIZER VS PLACEBO P... | 2008-05-23 | due-trials |
| Reported results | 2005-004227-19 | A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS W... | 2007-02-08 | due-trials |
| Reported results | 2005-004230-40 | A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias | 2015-07-30 | due-trials |
| Reported results | 2005-004249-33 | A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for... | 2006-11-17 | due-trials |
| Reported results | 2005-004250-28 | A MULTICENTER, RANDOMIZED, OPEN-LABEL COMPARISON OF THE SAFETY AND EFFICACY OF TIGECYCLINE WITH THAT OF AMPICILLIN-SULBACTAM OR AMOXICILLIN-CLAVULANATE TO TREAT COMPLICATED SKIN AND SKIN STRUCTURE INF... | 2008-09-22 | due-trials |
| Reported results | 2005-004270-25 | Double-blind, parallel-group, randomized, study of the efficacy and safety of continuous use of celecoxib vs the “usual use” of celecoxib in the treatment of subjects with chronicosteoarthritis of the... | 2008-02-21 | due-trials |
| Reported results | 2005-004391-21 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE... | 2008-01-10 | due-trials |
| Reported results | 2005-004411-29 | A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi... | 2009-03-02 | due-trials |
| Reported results | 2005-004412-70 | A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH 40-WEEK FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE FOR SMOKING CESSATION IN PATIENTS WITH M... | 2009-04-30 | due-trials |
| Reported results | 2005-004452-13 | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO... | 2007-07-13 | due-trials |
| Reported results | 2005-004514-32 | A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A... | 2009-08-07 | due-trials |
| Reported results | 2005-004534-40 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF PANTOPRAZOLE SODIUM ENTERIC-COATED GRANULES IN INFANTS (1 THROUGH 11 MONTHS) WITH ... | 2020-11-26 | due-trials |
| Reported results | 2005-004555-35 | INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG... | 2008-07-17 | due-trials |
| Reported results | 2005-004557-10 | INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN... | 2008-06-25 | due-trials |
| Reported results | 2005-004648-30 | A randomized double blind, placebo controlled balanced 4-way crossover study to assess the efficacy of single oral doses of PF-00592379 on erectile function, using 100mg sildenafil as a positive contr... | 2006-06-29 | due-trials |
| Reported results | 2005-004770-24 | A Phase 3, Randomized, Active-controlled, Double-Blind Trial of the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococca... | 2008-08-26 | due-trials |
| Completed, but no date, and reported results | 2005-004771-38 | A phase 3, randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healhy Infants Given With Routine ... | bad-data | |
| Reported results | 2005-004772-21 | A Phase 3, Randomized, Active-Controlled, Double-Blind, Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine... | 2008-07-28 | due-trials |
| Reported results | 2005-004780-34 | An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with... | 2007-07-17 | due-trials |
| Reported results | 2005-004941-33 | A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF SU-014813 IN PATIENTS WITH METASTATIC BREAST CANCER | 2009-07-09 | due-trials |
| Reported results | 2005-005130-12 | A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine... | 2008-10-21 | due-trials |
| Reported results | 2005-005179-14 | A PHASE 2B, RANDOMIZED, MULTICENTER, DOSE-RANGING STUDY ASSESSING THE SAFETY AND EFFICACY OF PD 0348292 IN THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN SUBJECTS UNDERGOING AN ELECTIVE, UNI... | 2007-07-27 | due-trials |
| Trial is partly outside EEC, and reported results | 2005-005246-40 | A Multicenter, Open-Label Study to Compare On-Demand Treatment With 2 Prophylaxis Regimens of Recombinant Coagulation Factor IX BeneFIX Reformulated Drug Product rFIX-R in Subjects With Severe Hem... | 2010-10-12 | bad-data |
| Reported results | 2005-005335-94 | A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL | 2011-12-16 | due-trials |
| Reported results | 2005-005463-28 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 2 FIXED DOSES (50 mg, 100 mg) OF DESVENLAFAXINE SUSTAINED-RELEASE TABLETS IN AD... | 2007-01-22 | due-trials |
| Reported results Terminated | 2005-005501-28 | Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. | 2009-03-24 | due-trials |
| Reported results Terminated | 2005-005502-23 | 26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia. | 2009-03-24 | due-trials |
| Completed, but no date, and reported results | 2005-005543-25 | Phase II Study of SKI-606 in Subjects with Advanced or Metastatic Breast Cancer | bad-data | |
| Reported results | 2005-005555-17 | S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA... | 2007-10-15 | due-trials |
| Reported results | 2005-005587-82 | A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS | 2008-03-18 | due-trials |
| Reported results | 2005-005593-79 | A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency | 2007-11-29 | due-trials |
| Reported results | 2005-005936-29 | A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis | 2007-05-07 | due-trials |
| Completed, but no date, and reported results | 2005-006022-29 | RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF ERLOTINIB WITH OR WITHOUT SU011248 IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER | bad-data | |
| Reported results Terminated | 2005-006026-28 | Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy | 2010-09-24 | due-trials |
| Reported results | 2006-000058-35 | A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® [Paracetamol (500mg) and Pseudoephedrine (30mg)] on subjects with nasal congestion accompanied by ... | 2008-03-25 | due-trials |
| Completed, but no date, and reported results | 2006-000068-10 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMEN... | bad-data | |
| Reported results | 2006-000224-13 | AN EXPLORATIVE STUDY OF TOLERABILITY AND PHARMACOKINETICS OF SU011248 IN COMBINATION WITH DOCETAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER | 2009-02-16 | due-trials |
| Reported results | 2006-000425-57 | A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA | 2008-02-01 | due-trials |
| Reported results | 2006-000568-95 | Phase 2 randomized non-comparative study of Ticilimumab or Best Supportive Care (BSC) immediately following first-line platinum-based therapy in patients with stage IIIB (with effusion) or stage IV no... | 2010-02-03 | due-trials |
| Reported results | 2006-001061-42 | An open-label, multicentre, supplementary and extension study of Etanercept in subjects with Ankylosing Spondylitis (AS) | 2008-10-07 | due-trials |
| Reported results | 2006-001132-45 | A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANT... | 2008-01-29 | due-trials |
| Completed, but no date, and reported results | 2006-001151-35 | AN EXPLORATIVE STUDY OF THE TOLERABILITY OF SU011248 IN COMBINATION WITH DOCETAXEL AND TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER OVER-EXPRESSING HER-2 | bad-data | |
| Reported results | 2006-001267-33 | PHASE 3 RANDOMIZED, MULTI CENTER STUDY OF SUNITINIB MALATE (SU 011248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER WHO FAILED BOTH A TAXANE AND AN ANTHRACYCLINE CHEMOTHERAPY REGIMEN OR FAI... | 2011-06-15 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-001270-24 | Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum | bad-data | |
| Reported results Terminated | 2006-001307-11 | A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (... | 2008-08-04 | due-trials |
| Reported results | 2006-001322-25 | A PHASE 2b MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS... | 2007-07-11 | due-trials |
| Reported results | 2006-001343-55 | A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). | 2007-10-15 | due-trials |
| Reported results | 2006-001347-66 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY | 2008-08-14 | due-trials |
| Reported results | 2006-001464-23 | A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS... | 2013-08-20 | due-trials |
| Reported results | 2006-001473-24 | A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS W... | 2007-12-20 | due-trials |
| Reported results | 2006-001474-24 | A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD | 2008-03-25 | due-trials |
| Reported results Terminated | 2006-001588-52 | A RANDOMIZED PHASE II TRIAL OF PEMETREXED WITH OR WITHOUT PF- 3512676 FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF ONE PRIOR CHEMOTH... | 2008-01-31 | due-trials |
| Trial is outside EEC, and reported results | 2006-001685-16 | A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy ... | bad-data | |
| Reported results | 2006-001831-23 | A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures | 2010-03-30 | due-trials |
| Reported results | 2006-001832-34 | A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-of-Care Controlled, Feasibility and Safety Study of rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal Femur | 2010-06-22 | due-trials |
| Reported results | 2006-001840-30 | A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA | 2008-02-13 | due-trials |
| Reported results | 2006-001916-54 | A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus | 2010-02-23 | due-trials |
| Reported results | 2006-001996-39 | AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS | 2009-04-29 | due-trials |
| Reported results | 2006-002053-69 | FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN | 2010-09-30 | due-trials |
| Reported results | 2006-002061-39 | A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant and Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 and QS-21 Adjuvant in S... | 2013-02-21 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-002228-40 | A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS | 2013-10-29 | bad-data |
| Trial is partly outside EEC, and reported results | 2006-002235-25 | A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension | 2008-06-05 | bad-data |
| Reported results | 2006-002257-76 | A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes... | 2009-03-18 | due-trials |
| Ongoing | 2006-002286-40 | Chronic Pain Management after Herniorraphy Pregabaline versus Placebo | not-yet-due | |
| Reported results Terminated | 2006-002303-14 | PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER | 2014-01-02 | due-trials |
| Reported results | 2006-002349-35 | Estudio piloto randomizado, doble ciego, multicéntrico a 12 semanas para evaluar el efecto de etanercept 100mg y 50mg semanales en sujetos con espondilitis anquilosante. A 12-week randomized, doubl... | 2008-08-06 | due-trials |
| Reported results | 2006-002414-35 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain. | 2007-06-21 | due-trials |
| Reported results | 2006-002420-41 | A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Recipien... | 2010-05-21 | due-trials |
| Reported results | 2006-002486-39 | A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN | 2012-05-22 | due-trials |
| Reported results | 2006-002576-18 | A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT | 2012-09-24 | due-trials |
| Reported results | 2006-002578-23 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC OB... | 2008-07-16 | due-trials |
| Reported results | 2006-002590-44 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSE REGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILY FOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEE | 2007-11-19 | due-trials |
| Reported results | 2006-002748-27 | A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis | 2009-05-15 | due-trials |
| Reported results | 2006-002749-35 | A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in Spondylarthropathy | 2008-12-11 | due-trials |
| Reported results | 2006-002792-41 | Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study | 2009-06-30 | due-trials |
| Reported results Terminated | 2006-002917-11 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN SUBJECTS WITH ADVANCED COLORECTAL CANCER | 2008-07-15 | due-trials |
| Exempt, with results | 2006-003215-52 | A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer. | 2018-05-23 | not-yet-due |
| Reported results | 2006-003475-13 | A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE... | 2009-03-31 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-003491-35 | A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND-DOUBLE DUMMY STUDY, TO EVALUATE EFFICACY AND SAFETY OF TREATMENT WITH AZITHROMYCIN, MICROSPHERES, ORAL POWDER FOR SUSPENSION, 2 G, IN ONE ADMINISTRAT... | bad-data | |
| Reported results | 2006-003577-27 | "ESTUDIO DE FASE IIA, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOCE SEMANAS DE DURACIÓN PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE PH-797804 ADMINISTRADO POR VIA ORAL UNA V... | 2008-07-17 | due-trials |
| Reported results | 2006-003897-87 | A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PPM-204 IN SUBJECTS WITH TYPE 2 DIABETES | 2007-10-23 | due-trials |
| Reported results | 2006-004022-87 | A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS | 2009-04-15 | due-trials |
| Reported results | 2006-004024-37 | SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ... | 2017-09-07 | due-trials |
| Reported results | 2006-004273-10 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous (IV) Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus | 2008-11-20 | due-trials |
| Completed, but no date, and reported results Terminated | 2006-004304-39 | NEUROMUSCULAR CHANGES IN SMALL FOR GESTATIONAL AGE (SGA-) CHILDREN DURING SOMATROPIN THERAPY - A PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER TRIAL (SGA-POWER STUDY) | bad-data | |
| Reported results | 2006-004306-50 | A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC | 2010-06-30 | due-trials |
| Reported results | 2006-004309-24 | A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ... | 2009-11-23 | due-trials |
| Reported results | 2006-004378-28 | A MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED PROOF OF CONCEPT AND DOSE RANGING STUDY WITH AN ACTIVE CONTROL TO ASSESS THE EFFICACY AND SAFETY/TOLERABILITY OF UK-369,... | 2008-06-04 | due-trials |
| Reported results | 2006-004380-58 | A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT ... | 2008-06-13 | due-trials |
| Reported results | 2006-004421-28 | A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS... | 2008-08-29 | due-trials |
| Reported results | 2006-004451-38 | A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES | 2009-12-10 | due-trials |
| Reported results | 2006-004453-18 | A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly Fo... | 2009-08-03 | due-trials |
| Reported results | 2006-004454-25 | 'A multicenter double-blind, placebo-controlled randomized pilot study evaluating efficacy and safety of ETN in patients with moderate to severe plaque psoriasis after cessation of ciclosporin therapy... | 2009-11-24 | due-trials |
| Reported results | 2006-004624-36 | A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER | 2011-06-20 | due-trials |
| Reported results | 2006-004693-27 | A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS | 2011-07-15 | due-trials |
| Completed, but no date, and reported results | 2006-004794-10 | A CLUSTER RANDOMIZED TRIAL ON CARDIOVASCULAR RISK FACTOR MANAGEMENT: CADUET® VERSUS USUAL CARE IN SUBJECTS WITH HYPERTENSION AND ADDITIONAL CARDIOVASCULAR RISK FACTORS IN CLINICAL PRACTICE | bad-data | |
| Reported results | 2006-005035-19 | A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS. | 2017-10-26 | due-trials |
| Reported results | 2006-005036-24 | A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREA... | 2008-08-15 | due-trials |
| Reported results | 2006-005084-26 | A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS | 2009-02-11 | due-trials |
| Reported results | 2006-005137-38 | A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study To Explore And Compare Perceptions And Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector A... | 2009-05-20 | due-trials |
| Reported results | 2006-005192-18 | A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES ... | 2008-11-03 | due-trials |
| Reported results | 2006-005381-39 | A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROUSAL... | 2008-10-03 | due-trials |
| Reported results | 2006-005476-40 | PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA. | 2011-12-15 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-005573-21 | A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE... | 2014-06-10 | bad-data |
| Reported results | 2006-005575-17 | An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children... | 2018-04-18 | due-trials |
| Trial is outside EEC, and reported results | 2006-005687-44 | A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients | bad-data | |
| Reported results | 2006-006070-22 | A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS | 2007-10-11 | due-trials |
| No trial status on register, and reported results | 2006-006204-11 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine | bad-data | |
| Reported results | 2006-006309-96 | A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjector a... | 2009-04-22 | due-trials |
| Reported results | 2006-006339-31 | AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESPOND... | 2008-01-31 | due-trials |
| Reported results | 2006-006373-25 | A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 | 2012-03-27 | due-trials |
| Exempt, with results | 2006-006412-29 | A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer | 2018-02-07 | not-yet-due |
| Exempt, with results Terminated | 2006-006413-33 | A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | 2008-03-27 | not-yet-due |
| Reported results | 2006-006538-16 | AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN... | 2014-08-12 | due-trials |
| Reported results | 2006-006591-37 | A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector ... | 2009-04-13 | due-trials |
| Reported results | 2006-006656-35 | "A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Low... | 2008-06-20 | due-trials |
| Reported results | 2006-006748-76 | A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA... | 2010-03-23 | due-trials |
| Completed, but no date, and reported results | 2006-006768-53 | A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 D... | bad-data | |
| Reported results | 2006-006779-19 | A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination Wi... | 2008-03-31 | due-trials |
| Reported results | 2006-006821-15 | A RANDOMISED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, MULTICENTRE STUDY IN ASYMPTOMATIC HIV-INFECTED PATIENTS TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERATION OF ... | 2008-09-15 | due-trials |
| Reported results | 2006-006935-38 | 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W... | 2008-07-17 | due-trials |
| Reported results Terminated | 2006-007034-36 | A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS W... | 2007-10-26 | due-trials |
| Reported results | 2007-000042-12 | A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACEBO ... | 2007-11-09 | due-trials |
| Reported results | 2007-000062-20 | A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy | 2013-07-01 | due-trials |
| Reported results | 2007-000084-24 | A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE TREATMENT OF PATIENTS WITH POST-SURGICAL PAIN FROM HYSTERECTOMY | 2012-05-22 | due-trials |
| Reported results | 2007-000219-27 | An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigators Choice Therapy in Subjects With Relapsed or ... | 2011-07-04 | due-trials |
| Reported results | 2007-000304-32 | Estudio fase 3, randomizado, controlado, doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de la Vacuna Neumocócica Conjugada 13-valente en niños sanos administrada con la vacuna... | 2009-03-23 | due-trials |
| Reported results | 2007-000325-21 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT | 2010-03-09 | due-trials |
| Exempt, with results | 2007-000371-42 | A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors | 2012-01-04 | not-yet-due |
| Reported results | 2007-000703-15 | A 14 MONTH, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF CP 945,598 IN PREVENTION OF WEIGHT REGAIN IN OBESE SUBJECTS | 2008-11-03 | due-trials |
| Reported results Terminated | 2007-000790-36 | Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study) | 2008-12-15 | due-trials |
| Reported results | 2007-000854-30 | A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional ... | 2012-07-27 | due-trials |
| Reported results | 2007-000896-41 | A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO... | 2011-05-30 | due-trials |
| Reported results | 2007-001035-58 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEI... | 2008-10-07 | due-trials |
| Completed, but no date, and reported results Terminated | 2007-001036-31 | A 2-COHORT, MULTI-CENTRE, RANDOMIZED, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 4-WAY CROSSOVER STUDY TO ASSESS THE EFFICACY OF SINGLE ORAL DOSES OF PF-00446687 ON ERECTILE FUNCTION IN MEN SUF... | bad-data | |
| Reported results | 2007-001037-34 | PHASE 2A MULTI-CENTRE, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 3-WAY CROSS-OVER STUDY TO INVESTIGATE THE EFFECT OF SINGLE DOSES OF PF-00446687 ON SEXUAL AROUSAL AND SEXUAL DESIRE IN WOMEN SU... | 2008-02-25 | due-trials |
| Reported results | 2007-001298-27 | A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Intravenous Methylnaltrexone (MOA 728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair | 2008-12-02 | due-trials |
| Reported results | 2007-001457-26 | A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOAR... | 2011-11-09 | due-trials |
| Reported results | 2007-001458-22 | "ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS CRI... | 2012-05-25 | due-trials |
| Reported results | 2007-001487-67 | A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FO... | 2008-11-25 | due-trials |
| Reported results | 2007-001568-66 | A RANDOMIZED, DOUBLE BLIND PHASE 3 STUDY OF GEMCITABINE PLUS AG 013736 VERSUS GEMCITABINE PLUS PLACEBO FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC PANCRE... | 2011-01-12 | due-trials |
| Reported results | 2007-001625-10 | AN OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE RADIOGRAPHIC EFFICACY AND SAFETY OF ENBREL™ (ETANERCEPT) ADDED TO METHOTREXATE IN COMPARISON WITH USUAL TREATMENT IN SUBJECTS WITH MODERATE RHEUMATOID A... | 2010-01-27 | due-trials |
| Reported results | 2007-001675-11 | A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus | 2013-09-09 | due-trials |
| Reported results | 2007-001724-12 | A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis | 2010-01-18 | due-trials |
| Exempt, with results | 2007-001767-30 | PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE MULTIPLE-DOSE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VARENICLINE IN HEALTHY ADOLESCENT SMOKERS | 2007-12-01 | not-yet-due |
| Reported results | 2007-001915-52 | A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB | 2012-12-20 | due-trials |
| Reported results | 2007-001922-28 | "Estudio en fase 2a, aleatorizado, controlado con placebo, en grupos paralelos, de dosis múltiples para evaluar la eficacia, la seguridad y la tolerabilidad de la administración oral durante 12 semana... | 2008-06-26 | due-trials |
| Reported results | 2007-001984-31 | A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NO... | 2010-04-16 | due-trials |
| Reported results | 2007-002066-35 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE T... | 2009-01-14 | due-trials |
| Trial is partly outside EEC, and reported results | 2007-002120-14 | A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections | 2009-09-25 | bad-data |
| Reported results | 2007-002326-29 | A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactiva... | 2008-02-13 | due-trials |
| Reported results | 2007-002381-36 | A MULTI-CENTER, LONG TERM, OPEN-LABEL STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIA | 2009-06-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-002445-20 | A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS... | 2011-05-12 | bad-data |
| Reported results | 2007-002683-10 | A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who R... | 2009-04-16 | due-trials |
| Reported results | 2007-002969-12 | A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER | 2010-08-15 | due-trials |
| Reported results | 2007-002987-84 | A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER | 2011-07-06 | due-trials |
| Reported results Terminated | 2007-003096-39 | Effects of Etanercept on Endothelial Function and Carotid Intima-Media Thickness In Patients With Active Ankylosing Spondylitis: a 52-Weeks, Randomized, Double Blind, Placebo-Controlled Study | 2011-10-25 | due-trials |
| Reported results | 2007-003161-40 | A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES | 2013-07-24 | due-trials |
| Reported results | 2007-003293-25 | A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE | 2008-06-30 | due-trials |
| Reported results | 2007-003586-41 | PLACEBO-CONTROLLED TRIAL ON THE EFFICACY OF GROWTH HORMONE REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY AFTER TRAUMATIC BRAIN INJURY | 2009-01-20 | due-trials |
| Reported results | 2007-003656-11 | A RANDOMIZED, DOUBLE BLIND MULTI CENTER DOSE RANGING STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE ADJUNCTIVE TREATMENT OF POST SURGICAL PAIN AFTER PRIMARY INGUINAL HERNIA ... | 2009-09-18 | due-trials |
| Reported results | 2007-003780-50 | A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | 2015-06-27 | due-trials |
| Reported results | 2007-003793-26 | Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacient... | 2015-04-27 | due-trials |
| Reported results | 2007-003949-32 | A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN) | 2013-12-30 | due-trials |
| Reported results | 2007-004017-33 | Reformulated BeneFIX efficacy and safety after conversion from a pdFIX. | 2009-01-20 | due-trials |
| Reported results | 2007-004379-20 | A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE F... | 2011-10-14 | due-trials |
| Reported results | 2007-004392-19 | "Ensayo en fase 2b multicéntrico, aleatorizado, comparativo de UK 453,061 frente a etravirina en combinación con darunavir/ritonavir y un inhibidor de la transcriptasa inversa análogos de los nucleósi... | 2012-10-18 | due-trials |
| Completed, but no date, and reported results | 2007-004465-18 | A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared With a 23-Valent P... | bad-data | |
| Reported results | 2007-004466-41 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH MODE... | 2010-12-14 | due-trials |
| Exempt, with results | 2007-004486-17 | A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING S SARCOMA FAMILY OF TUMORS STUDIO DI FASE 1/FASE 2 SUL CP-751,871 IN PAZIENTI CON TUMORI DELLA FAMIGLIA DEL ... | 2012-10-24 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2007-004543-30 | A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE MASKED, 12 WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA | 2009-11-11 | bad-data |
| Reported results | 2007-004555-11 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS AN "ADD-ON" THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS UNDER MONOTHERAPY OF ... | 2009-02-03 | due-trials |
| Reported results | 2007-004733-41 | A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY | 2008-11-06 | due-trials |
| Reported results | 2007-004768-32 | LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER | 2012-04-02 | due-trials |
| Reported results | 2007-004787-49 | A PHASE II, SINGLE ARM STUDY OF CP-751,871 IN PATIENTS WITH REFRACTORY METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM | 2010-09-22 | due-trials |
| Reported results | 2007-004854-97 | OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE... | 2010-05-27 | due-trials |
| Reported results | 2007-004891-38 | A 12-week, phase 2A, radomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overwei... | 2008-11-25 | due-trials |
| Reported results Terminated | 2007-004918-14 | A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF DONEPEZIL HYDROCHLORIDE (ARICEPT®) ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH SEVERE ALZHEIMER’S DISEASE | 2008-05-09 | due-trials |
| Reported results | 2007-005695-14 | A Double-Blind, Placebo-Controlled, Randomized, Single-Dose, 2-Period Crossover Study of the Pharmacodynamics of Orally Administered PSI-697 in Healthy Subjects Who Smoke | 2008-08-07 | due-trials |
| Reported results | 2007-005781-12 | A FOUR WEEK, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF PH-797804 IN THE TREATMENT OF POST-HERPETIC NEURALGIA | 2008-12-05 | due-trials |
| Reported results | 2007-005784-10 | A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO... | 2010-10-05 | due-trials |
| Reported results | 2007-005912-23 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE ... | 2009-12-18 | due-trials |
| Reported results | 2007-005994-79 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ... | 2012-11-27 | due-trials |
| Reported results | 2007-005995-14 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ... | 2012-12-03 | due-trials |
| Reported results | 2007-006107-20 | Estudio de extensión abierto para evaluar la seguridad de una dosis fija de metilnaltrexona subcutánea en sujetos con enfermedad avanzada y estreñimiento inducido por opiáceos Open-Label Extension St... | 2012-09-27 | due-trials |
| Reported results | 2007-006150-25 | A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable... | 2012-10-24 | due-trials |
| Reported results | 2007-006283-30 | A RANDOMIZED, PHASE 2 STUDY OF FOLFOX OR FOLFIRI WITH AG-013736 OR BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER AFTER FAILURE OF AN IRINOTECAN OR OXALIPLATINCONTAINING FIRST-LINE REGIMEN | 2012-04-12 | due-trials |
| Reported results | 2007-006451-39 | 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W... | 2009-10-20 | due-trials |
| Reported results | 2007-006637-14 | "Estudio en fase 3, abierto, aleatorizado, multinacional de malato de sunitinib frente a sorafenib en pacientes con carcinoma hepatocelular avanzado" A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 ... | 2011-12-08 | due-trials |
| Reported results | 2007-006657-63 | Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA) | 2012-06-20 | due-trials |
| Reported results | 2007-006682-33 | Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer | 2012-10-16 | due-trials |
| Reported results | 2007-006791-12 | The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis | 2010-02-18 | due-trials |
| Reported results | 2007-007087-17 | A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF... | 2010-09-08 | due-trials |
| Reported results | 2007-007456-34 | A Phase 2, Multicenter, Randomized, Active-Controlled, Parallel-Group, Dose-Finding and Safety Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) in Subje... | 2015-04-24 | due-trials |
| Reported results | 2007-007588-26 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND... | 2008-08-26 | due-trials |
| Reported results | 2007-007859-14 | A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WITH ... | 2009-07-07 | due-trials |
| Exempt, with results | 2007-007885-39 | A Phase 1/2 Study of HKI-272 in Combination with Vinorelbine in Subjects with Solid Tumors and Metastatic Breast Cancer | 2018-06-07 | not-yet-due |
| Reported results | 2007-007888-24 | Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept. | 2010-04-09 | due-trials |
| Reported results | 2008-000023-26 | A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community Acquired Pneumonia and Invasive P... | 2013-10-01 | due-trials |
| Reported results | 2008-000025-19 | "ESTUDIO DE PREGABALINA, ALEATORIZADO, DOBLE CIEGO, DE 6 SEMANAS DE DURACIÓN EN SUJETOS CON SÍNDROME DE PIERNAS INQUIETAS" RANDOMIZED, DOUBLE-BLIND, 6-WEEK STUDY OF PREGABALIN IN SUBJECTS WITH RESTLE... | 2009-01-17 | due-trials |
| Reported results | 2008-000095-25 | CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease | 2009-12-10 | due-trials |
| Reported results | 2008-000327-25 | "ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS R... | 2009-02-04 | due-trials |
| Reported results | 2008-000345-55 | ESTUDIO DE FASE III, RANDOMIZADO Y ABIERTO DE CP-751.871 EN COMBINACIÓN CON PACLITAXEL Y CARBOPLATINO VERSUS PACLITAXEL Y CARBOPLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO. RANDOMIZED, OPE... | 2012-09-25 | due-trials |
| Reported results Terminated | 2008-000349-68 | A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS) STUDIO PROS... | 2011-01-31 | due-trials |
| Reported results | 2008-000355-94 | AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AND N... | 2008-11-21 | due-trials |
| Reported results | 2008-000412-33 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUIRED... | 2011-07-15 | due-trials |
| Reported results | 2008-000546-31 | A RANDOMIZED, MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY OF VARENICLINE IN CESSATION OF ORAL TOBACCO USE | 2009-07-16 | due-trials |
| Reported results Terminated | 2008-000761-32 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G... | 2009-03-27 | due-trials |
| Reported results Terminated | 2008-000762-23 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF ... | 2009-03-27 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-000763-42 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF GENE... | bad-data | |
| Trial is partly outside EEC, and reported results | 2008-000844-15 | A PHASE 1, OPEN-LABEL STUDY OF LATANOPROST ACID PLASMA CONCENTRATIONS IN PEDIATRIC AND ADULT GLAUCOMA PATIENTS TREATED WITH LATANOPROST 0.005% | 2009-03-26 | bad-data |
| Reported results | 2008-000986-42 | A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER... | 2011-08-16 | due-trials |
| Ongoing, reported early | 2008-000989-23 | A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED CP-675,206 IN OTHER PROTOCOLS | not-yet-due | |
| Reported results | 2008-001168-35 | ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA. | 2012-04-26 | due-trials |
| Reported results | 2008-001262-87 | An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy | 2010-12-15 | due-trials |
| Ongoing | 2008-001298-13 | A RANDOMIZED PHASE 2, OPEN-LABEL STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL AND DOCETAXEL ALONE AS A FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED BREAST CANCER | not-yet-due | |
| Reported results | 2008-001396-30 | A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MOD... | 2009-03-02 | due-trials |
| Reported results | 2008-001451-21 | AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL | 2016-02-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-001457-18 | Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants | bad-data | |
| Reported results | 2008-001497-33 | PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF... | 2009-12-10 | due-trials |
| Reported results | 2008-001566-90 | A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI... | 2010-10-06 | due-trials |
| Reported results | 2008-001635-34 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | 2013-06-27 | due-trials |
| Reported results | 2008-001662-85 | A Phase 1/2 Open-label Study of Neratinib (HKI-272) in combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally advanced Breast Cancer | 2018-06-01 | due-trials |
| Reported results | 2008-001726-13 | PHASE 2 TRIAL OF AG-013736 AS FIRST-LINE TREATMENT FOR PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER RECEIVING TREATMENT WITH CISPLATIN AND GEMCITABINE | 2011-11-30 | due-trials |
| Trial is outside EEC, and reported results | 2008-001875-32 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (DVS SR) In The Treatm... | bad-data | |
| Trial is outside EEC, and reported results | 2008-001876-67 | A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the T... | bad-data | |
| Trial is partly outside EEC | 2008-001936-11 | A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Includ... | 2014-12-12 | bad-data |
| Trial is outside EEC, and reported results | 2008-002063-13 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fluoxetine-Referenced Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release ... | bad-data | |
| Trial is outside EEC, and reported results | 2008-002064-34 | A 6-MONTH, OPEN-LABEL, MULTI-CENTER, FLEXIBLE-DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED-RELEASE (DVS SR) TABLET... | bad-data | |
| Trial is outside EEC, and reported results | 2008-002066-57 | Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Sustaine... | bad-data | |
| Trial is outside EEC, and reported results | 2008-002067-14 | 6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outp... | bad-data | |
| Reported results | 2008-002158-40 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO... | 2011-12-21 | due-trials |
| Completed, but no date, and reported results | 2008-002208-24 | A FOUR WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF VARENICLINE TARTRATE (CP-526,555) IN THE TREATMENT OF POST-HERPETIC NEURALGIA | bad-data | |
| Reported results | 2008-002345-23 | A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS | 2015-06-09 | due-trials |
| Reported results | 2008-002392-27 | "Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer... | 2017-12-20 | due-trials |
| Reported results | 2008-002421-37 | A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS AS... | 2010-01-19 | due-trials |
| Trial is outside EEC, and reported results | 2008-002456-24 | A Post Authorization Safety Surveillance Study of Xyntha in Usual Care Settings | bad-data | |
| Reported results | 2008-002457-20 | "Estudio de fase 2, aleatorizado y abierto, de bosutinib administrado en combinación con exemestano frente a exemestano solo como tratamiento de segunda línea en mujeres posmenopáusicas con cáncer de ... | 2010-05-31 | due-trials |
| Reported results | 2008-002623-85 | A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE | 2012-12-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-002774-34 | A 8-WEEK, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | bad-data | |
| Reported results | 2008-003203-32 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OSTEOP... | 2011-02-07 | due-trials |
| Reported results | 2008-003210-10 | "PHASE II MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR DEGENERATION, COMPARATOR CONTROLLED, DOSE RANGING STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB IN THE TREATMENT OF SUBJECTS WITH ... | 2011-07-07 | due-trials |
| Reported results | 2008-003571-45 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHNS DISEASE | 2009-10-29 | due-trials |
| Reported results | 2008-003572-21 | A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY INVESTIGATING THE DOSE-RESPONSE OF PF-00489791 ON ACUTE HEMODYNAMICS IN SUBJECTS WITH IDIOPATHIC AND FAMILIAL PULMONARY A... | 2010-07-28 | due-trials |
| Reported results | 2008-003631-21 | A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Preven... | 2010-06-23 | due-trials |
| Trial is outside EEC, and reported results | 2008-003648-12 | A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity, and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children | bad-data | |
| Trial is outside EEC, and reported results | 2008-003687-20 | A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine ... | bad-data | |
| Trial is outside EEC, and reported results | 2008-003688-38 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With... | bad-data | |
| Trial is outside EEC, and reported results | 2008-003708-77 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Impact of a 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus ... | bad-data | |
| Reported results | 2008-004008-30 | RANDOMIZED, OPEN LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFECT OF THE ADDITION OF CP-751,871 TO GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER | 2010-03-24 | due-trials |
| Reported results | 2008-004009-32 | Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso. | 2012-03-28 | due-trials |
| Reported results Terminated | 2008-004088-21 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS | 2008-09-09 | due-trials |
| Reported results | 2008-004124-23 | A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder | 2010-01-14 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-004150-32 | A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA | 2018-02-14 | bad-data |
| Reported results | 2008-004183-38 | ENSAYO ALEATORIZADO, CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE CP 533,536 EN PACIENTES CON FRACTURA CERRADA DE LA DIAFASIS TIBIAL A RANDOMIZED, PLACEBO-CONTRO... | 2010-05-13 | due-trials |
| Reported results | 2008-004439-39 | Estudio abierto y aleatorizado, comparativo de dos estrategias diferentes en el tratamiento de sujetos con psoriasis en placas que han respondido a la administración de etanercept. Randomized Open-la... | 2013-04-23 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-004443-11 | A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER | bad-data | |
| Reported results | 2008-004564-40 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | 2010-09-06 | due-trials |
| Trial is outside EEC, and reported results | 2008-004765-26 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine... | bad-data | |
| Trial is outside EEC, and reported results | 2008-004766-40 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine... | bad-data | |
| Trial is outside EEC, and reported results | 2008-004767-19 | A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan | bad-data | |
| Trial is outside EEC, and reported results | 2008-004768-38 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine... | bad-data | |
| Trial is outside EEC, and reported results | 2008-004769-24 | Phase 2, Randomized, Active-Controlled, Double-Blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine P... | bad-data | |
| Reported results | 2008-004815-37 | "ESTUDIO FASE III, MULTICÉNTRICO, CONTROLADO, DOBLE CIEGO Y ALEATORIZADO SOBRE LA SEGURIDAD Y EFICACIA ANALGÉSICA A LARGO PLAZO DE TANEZUMAB EN MONOTERAPIA O EN COMBINACIÓN CON ANTIINFLAMATORIOS NO ES... | 2010-10-28 | due-trials |
| Reported results | 2008-004861-25 | A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED... | 2010-03-17 | due-trials |
| Trial is partly outside EEC | 2008-005166-31 | A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-a... | 2014-12-12 | bad-data |
| Reported results | 2008-005181-31 | PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES | 2012-02-07 | due-trials |
| Reported results | 2008-005182-66 | PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES | 2013-02-14 | due-trials |
| Reported results | 2008-005235-14 | A RANDOMIZED PHASE 2 TRIAL OF PF 00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN | 2015-08-15 | due-trials |
| Reported results | 2008-005249-51 | A PHASE 2B, PARALLEL GROUP, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK ONCE DAILY ADMINISTRATION OF INHALED PF-00610355 DRY POWDER IN P... | 2010-12-20 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-005275-10 | "Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones po... | 2013-07-08 | bad-data |
| Reported results | 2008-005277-35 | EFFICACY AND SAFETY OF ERAXIS/ECALTA (ANIDULAFUNGIN) COMPARED TO CANCIDAS (CASPOFUNGIN) IN NEUTROPENIC PATIENTS WITH INVASIVE CANDIDA INFECTION | 2012-05-18 | due-trials |
| Reported results Terminated | 2008-005278-11 | EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION | 2012-06-08 | due-trials |
| Completed, but no date, and reported results | 2008-005350-21 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY OF THE EFFICACY OF FESOTERODINE IN INCREASING URETHRAL PRESSURE IN STRESS URINARY INCONTINENCE PATIENTS | bad-data | |
| Reported results | 2008-005424-85 | A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor... | 2011-03-22 | due-trials |
| Reported results | 2008-005425-11 | A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer | 2018-06-20 | due-trials |
| Reported results | 2008-005692-10 | A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Relate... | 2009-08-10 | due-trials |
| Reported results Terminated | 2008-005885-30 | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION | 2011-01-31 | due-trials |
| Reported results Terminated | 2008-005886-78 | A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PUL... | 2010-12-08 | due-trials |
| Reported results Terminated | 2008-005887-14 | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WIT... | 2011-01-31 | due-trials |
| Reported results | 2008-005889-32 | RANDOMIZED DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALINA IN SUBJECTS WITH RESTLESS LEGS SYNDROME. Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de p... | 2011-04-28 | due-trials |
| Reported results | 2008-005935-14 | An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain Estudio abierto para evaluar la seguridad a... | 2010-09-20 | due-trials |
| Reported results | 2008-005961-77 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation Estudio multicéntrico, aleatorizado, en doble... | 2009-06-01 | due-trials |
| Reported results | 2008-006049-26 | "ESTUDIO DE CONTINUACIÓN ABIERTO, DE FASE 2B/3, PARA LOS SUJETOS QUE SE RETIREN DE LOS PROTOCOLOS UK 453,061 PARA EL TRATAMIENTO DE LA INFECCIÓN POR EL VIH 1" "A PHASE 2B/3 OPEN-LABEL ROLLOVER STUDY F... | 2013-07-15 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-006130-95 | A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | 2013-10-08 | bad-data |
| Reported results | 2008-006194-33 | Revaccination with Pneumococcal Conjugate Vaccine - Characterization of the Immune Response after Polysaccharide (REPLAY) | 2009-12-16 | due-trials |
| Reported results | 2008-006252-21 | A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastati... | 2010-05-31 | due-trials |
| Reported results | 2008-006352-22 | CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease | 2010-10-06 | due-trials |
| Completed, but no date Terminated | 2008-006760-10 | A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA | bad-data | |
| Reported results | 2008-006840-20 | Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients | 2013-08-07 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-006873-33 | AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP... | bad-data | |
| Reported results | 2008-006936-37 | A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Backg... | 2011-02-18 | due-trials |
| Reported results | 2008-007023-26 | PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE | 2012-02-10 | due-trials |
| Reported results | 2008-007038-24 | "Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH... | 2011-07-22 | due-trials |
| Completed, but no date Terminated | 2008-007183-42 | A PHASE IIb RANDOMISED DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-00610355 OVER 4 WEEKS IN MODERATE ASTHMATIC SUBJECTS | bad-data | |
| Exempt, with results | 2008-007185-33 | A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate | 2011-01-12 | not-yet-due |
| Reported results | 2008-007345-31 | A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer | 2019-10-04 | due-trials |
| Not reported Terminated | 2008-007510-30 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 12 WEEKS OF TREATMENT WITH ARR... | 2009-07-08 | due-trials |
| Reported results | 2008-007786-23 | ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXIT... | 2016-02-29 | due-trials |
| Reported results | 2008-007788-17 | PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS | 2010-06-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2008-007789-51 | A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg i... | 2014-03-27 | bad-data |
| Reported results | 2008-007802-12 | An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Tra... | 2012-10-31 | due-trials |
| Reported results | 2008-007803-10 | A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc... | 2018-06-29 | due-trials |
| Reported results | 2008-007997-39 | A Postauthorization Safety Surveillance Study of Patients Switching to ReFacto AF From ReFacto or Other Factor VIII Products in Usual Care Settings | 2013-03-28 | due-trials |
| Reported results | 2008-008005-21 | CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer s Disease on Donepezi... | 2012-01-12 | due-trials |
| Reported results | 2008-008337-11 | Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de... | 2011-01-17 | due-trials |
| Reported results | 2008-008338-35 | PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXAT... | 2012-09-14 | due-trials |
| Reported results | 2008-008339-27 | A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY | 2011-02-28 | due-trials |
| Reported results | 2008-008435-29 | A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A ... | 2016-04-05 | due-trials |
| Reported results | 2008-008436-93 | An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings | 2017-01-02 | due-trials |
| Reported results | 2009-009214-40 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT... | 2012-01-27 | due-trials |
| Reported results | 2009-009318-41 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP | 2010-11-24 | due-trials |
| Reported results | 2009-009324-36 | OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN ... | 2017-05-10 | due-trials |
| Reported results | 2009-010173-20 | A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY | 2010-07-29 | due-trials |
| Reported results | 2009-010516-15 | Ensayo aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de SBI-087 en sujetos seropositivos con artritis reumatoide activa en tratamie... | 2013-07-25 | due-trials |
| Reported results | 2009-010922-21 | A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with QS-21 Adjuvant in Subjects with Mild t... | 2013-12-17 | due-trials |
| Reported results | 2009-011014-17 | EFFECTS OF PREGABALIN ON SLEEP MAINTENANCE IN SUBJECTS WITH FIBROMYALGIA SYNDROME AND SLEEP MAINTENANCE DISTURBANCE: A RANDOMIZED PLACEBO-CONTROLLED 2-WAY CROSSOVER POLYSOMNOGRAPHY STUDY | 2010-06-03 | due-trials |
| Reported results | 2009-011172-30 | A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DI... | 2011-06-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-011396-77 | A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized Wi... | 2013-03-28 | bad-data |
| Reported results | 2009-011535-12 | Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis | 2020-07-08 | due-trials |
| Trial is outside EEC, and reported results | 2009-011564-11 | A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 2 and 3 Doses of 13-valent Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus-Infected S... | bad-data | |
| Reported results | 2009-011799-31 | A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Six-Month Safety and Efficacy Study of Dimebon in Patients with Moderate-to-Severe Alzheimer s Disease and Neuropsychiatric Symptoms | 2010-05-07 | due-trials |
| Reported results | 2009-011800-44 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease | 2011-02-15 | due-trials |
| Reported results | 2009-011878-15 | A phase 1/2, open-label study of bosutinib administered in combination with capecitabine in subjects with solid tumor and ErbB2 negative locally advanced or metastatic breast cancer. | 2011-03-31 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-012087-13 | A Phase 3, Open-label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine in Recipients... | 2013-05-17 | bad-data |
| Completed, but no date, and reported results | 2009-012179-82 | A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | bad-data | |
| Reported results Terminated | 2009-012456-25 | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHE... | 2010-05-07 | due-trials |
| Reported results | 2009-012504-13 | PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP... | 2015-12-29 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-012520-84 | A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related A... | 2013-01-30 | bad-data |
| Reported results | 2009-012595-27 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (N... | 2016-01-05 | due-trials |
| Exempt, with results | 2009-012769-74 | PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS | 2012-10-23 | not-yet-due |
| Trial is partly outside EEC, and reported results | 2009-012848-16 | A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGE... | 2014-06-13 | bad-data |
| Reported results | 2009-012857-39 | A PHASE 2, RANDOMIZED, OPEN LABEL STUDY OF FIGITUMUMAB (CP 751,871) PLUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE, VERSUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE ALONE, AS FIRST LINE TREATMENT IN PAT... | 2011-10-11 | due-trials |
| Reported results | 2009-013174-41 | AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Tr... | 2017-11-02 | due-trials |
| Reported results | 2009-013223-37 | "Estudio en fase 2a, aleatorizado, doble ciego, controlado con un fármaco activo y con placebo, de PF-04171327 en el tratamiento de los signos y síntomas de la artritis reumatoide" A PHASE 2A, RANDOM... | 2010-07-29 | due-trials |
| Reported results | 2009-013329-41 | A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip | 2011-02-04 | due-trials |
| Reported results | 2009-014269-25 | PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO | 2020-08-28 | due-trials |
| Reported results | 2009-014296-40 | PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE ... | 2011-05-17 | due-trials |
| Reported results | 2009-014492-46 | A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED, TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT rLP2086 VACCINE WHEN ADMINISTERED AS A 3-DOSE REGIMEN IN HEALTHY Y... | 2015-02-13 | due-trials |
| Reported results | 2009-014493-18 | A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in He... | 2013-05-16 | due-trials |
| Reported results | 2009-014540-11 | A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERAT... | 2010-06-15 | due-trials |
| Reported results | 2009-014597-17 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL C... | 2011-01-21 | due-trials |
| Reported results | 2009-014734-16 | A PHASE 2A RANDOMIZED, DOUBLE-BLINDED, DOUBLE DUMMY, PLACEBO AND ACTIVE CONTROLLED, TWO-WAY CROSS-OVER, FLARE-ENRICHED MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAI... | 2010-05-13 | due-trials |
| Reported results | 2009-014916-37 | "Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces al d... | 2012-06-13 | due-trials |
| Reported results | 2009-015079-29 | A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E... | 2012-11-01 | due-trials |
| Reported results | 2009-015080-13 | A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated ... | 2012-11-01 | due-trials |
| Trial is partly outside EEC, and reported results | 2009-015198-11 | A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healt... | 2014-09-26 | bad-data |
| Reported results | 2009-015321-37 | A Phase 3, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Pneumococcal Conjugate Vaccine in Healthy Children Who Have Been Previously Immunized With a 4-Dose Series of a... | 2010-11-17 | due-trials |
| Reported results | 2009-015498-11 | A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects With Relapsed, Refractory Mantle Cell Lymphoma | 2018-06-28 | due-trials |
| Ongoing | 2009-015515-40 | PREVENTION OF THE PROGRESSION OF VERY EARLY SYMPTOMS INTO ANKYLOSING SPONDYLITIS: A PLACEBO CONTROLLED TRIAL WITH ETANERCEPT | not-yet-due | |
| Reported results | 2009-015636-15 | An Open-label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis | 2012-02-08 | due-trials |
| Reported results Terminated | 2009-016248-37 | A SINGLE ARM SINGLE CENTRE STUDY TO INVESTIGATE SAFETY AND EFFICACY OF SILDENAFIL IN NEAR TERM AND TERM NEWBORNS WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN) | 2012-06-18 | due-trials |
| Reported results | 2009-016766-86 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA (PROTOCOL A008122... | 2014-09-03 | due-trials |
| Reported results Terminated | 2009-016849-25 | A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES | 2011-09-07 | due-trials |
| Reported results | 2009-016850-42 | AN OPEN-LABEL MULTICENTER EXTENSION STUDY TO DETERMINE LONG TERM SAFETY AND EFFICACY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES | 2011-12-26 | due-trials |
| Reported results | 2009-016987-34 | "Estudio de fase 3 aleatorizado y doble ciego de la eficacia y la seguridad de 2 dosis de CP-690,550 en comparación con metotrexato en pacientes con artritis reumatoide no tratados previamente con met... | 2013-03-13 | due-trials |
| Trial is outside EEC, and reported results | 2009-017122-39 | A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations... | bad-data | |
| Trial is outside EEC, and reported results | 2009-017304-88 | A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States | bad-data | |
| Reported results | 2009-017332-41 | A Phase 4, Open-label Trial Describing the Safety, Tolerability, and Immunogenicity of the 13 valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants | 2014-01-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2009-017354-12 | A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO ARM CROSS-OVER STUDY ASSESSING DYAD (SUBJECT AND CAREGIVER) AND ADULT SUBJECT PERCEPTION OF CONVENIENCE AND PREFERENCE OF THE NEWLY DEVELOPED GENOTROPIN MARK... | 2011-10-26 | bad-data |
| Reported results | 2009-018121-75 | CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease | 2012-04-20 | due-trials |
| Reported results | 2009-018123-32 | HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease | 2011-06-17 | due-trials |
| Reported results | 2010-018254-12 | A LOCAL, MULTICENTRE, OPEN-LABEL, EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER | 2012-04-03 | due-trials |
| Reported results | 2010-018585-23 | AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC) | 2021-04-29 | due-trials |
| Reported results | 2010-019009-40 | A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE... | 2011-05-31 | due-trials |
| Reported results | 2010-019035-35 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A... | 2012-08-01 | due-trials |
| Reported results | 2010-019521-34 | A 15 WEEK, RANDOMIZED, DOUBLE BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12-17 YEARS OLD) WITH FIBROMYALGIA | 2014-12-08 | due-trials |
| Reported results | 2010-019844-38 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2012-10-29 | due-trials |
| Reported results | 2010-019888-10 | PROSPECTIVE OPEN-LABEL INVESTIGATION OF THE NON-SURGICAL TREATMENT WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAPEX®) | 2012-10-31 | due-trials |
| Reported results | 2010-019988-10 | A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PS... | 2013-04-17 | due-trials |
| Reported results | 2010-020002-15 | A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | 2016-06-22 | due-trials |
| Reported results | 2010-020003-73 | A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PS... | 2013-04-24 | due-trials |
| Reported results | 2010-020004-30 | "Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea... | 2013-01-29 | due-trials |
| Reported results | 2010-020005-32 | A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ... | 2013-01-31 | due-trials |
| Reported results | 2010-020077-16 | A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 W... | 2016-03-05 | due-trials |
| Reported results | 2010-020147-12 | AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY C... | 2014-03-28 | due-trials |
| Completed, but no date, and reported results | 2010-020300-29 | A 6-MONTH, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN ADOLESCENT PATIENTS WITH FIBROMYALGIA | bad-data | |
| Reported results Terminated | 2010-020427-43 | A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY | 2010-10-28 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-020475-23 | A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY OR... | bad-data | |
| Exempt, with results | 2010-020730-26 | A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES | 2012-11-13 | not-yet-due |
| Reported results | 2010-020731-39 | A 12-MONTH OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES | 2013-10-09 | due-trials |
| Reported results | 2010-020764-38 | PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ACU... | 2011-08-04 | due-trials |
| Reported results | 2010-020821-41 | A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Na�ve Patients with Progressive Metastatic Prostate Cancer Who Have Fail... | 2019-02-14 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-020852-79 | A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES | 2016-08-10 | bad-data |
| Reported results Terminated | 2010-020860-39 | A LONG-TERM OPEN-LABEL EXTENSION STUDY OF LERSIVIRINE FOR THE TREATMENT OF HIV-1 INFECTION | 2013-04-30 | due-trials |
| Reported results | 2010-020890-18 | AN EXPLORATORY PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO ASSESS THE EFFECTS OF TOFACITINIB (CP-690,550) ON MAGNETIC RESONANCE IMAGING ENDPOINTS, IN METHOTREXATE NAÏVE SUBJECTS WITH EARLY... | 2013-11-05 | due-trials |
| Reported results | 2010-020946-80 | A PHASE IIIB, ONE YEAR, OPEN LABEL, MULTICENTRE, NONCOMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREAL PEGAPTANIB SODIUM INJECTION IN SUBJECTS WITH DIABETIC MACULAR EDEMA (DME) | 2012-07-12 | due-trials |
| Trial is partly outside EEC | 2010-021231-14 | A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIV... | 2012-03-26 | bad-data |
| Reported results | 2010-021266-30 | A FOLLOW UP INVESTIGATION FOR PATIENTS COMPLETING STUDY A1481276 TO INVESTIGATE DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS FOLLOWING COMPLETION OF SILDENAFIL TREATMENT | 2014-01-14 | due-trials |
| Reported results | 2010-021336-33 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE... | 2016-11-30 | due-trials |
| Reported results | 2010-021358-20 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-0048... | 2013-08-20 | due-trials |
| Reported results Terminated | 2010-021414-32 | A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE | 2013-11-05 | due-trials |
| Reported results | 2010-021590-37 | A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILUR... | 2017-01-20 | due-trials |
| Reported results | 2010-021788-33 | A PHASE 4, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VARENICLINE COMPARED TO PLACEBO FOR SMOKING CESSATION THROUGH REDUCTION | 2013-07-12 | due-trials |
| Reported results | 2010-021789-31 | A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIO... | 2012-11-02 | due-trials |
| Exempt, with results Terminated | 2010-022036-36 | A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma | 2016-11-22 | not-yet-due |
| Reported results | 2010-022303-22 | A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS THE IMPACT OF PROPHYLACTIC ANTIPYRETIC MEDICATION ON THE IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH ROUTINE PEDIATRIC VACCI... | 2013-01-16 | due-trials |
| Reported results | 2010-022449-38 | A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND BIVALENT rLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY ... | 2013-06-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2010-022475-55 | A 12-WEEK RANDOMIZED, OPEN-LABEL, ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12-WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND >25 KG W... | 2020-02-13 | bad-data |
| Reported results | 2010-022515-20 | PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA | 2013-06-06 | due-trials |
| Reported results | 2010-022656-22 | A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT ... | 2015-09-14 | due-trials |
| Reported results | 2010-022766-27 | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF MULTISTEM (PF-05285401) IN SUBJECTS WITH MODERATE TO SEVERE ULCERAT... | 2014-11-19 | due-trials |
| Reported results | 2010-022914-15 | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYDROC... | 2015-01-13 | due-trials |
| Reported results Terminated | 2010-022955-43 | OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS ... | 2012-04-04 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-022978-14 | PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS | 2023-04-14 | bad-data |
| Reported results | 2010-023017-65 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL DO... | 2014-10-29 | due-trials |
| Reported results | 2010-023034-23 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE) | 2015-02-26 | due-trials |
| Exempt, with results | 2010-023062-40 | A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors | 2017-01-30 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2010-023263-18 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | 2019-02-20 | bad-data |
| Reported results | 2010-023412-13 | A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mu... | 2023-02-06 | due-trials |
| Reported results | 2010-023437-30 | "Estudio doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de PF-00547659 en sujetos con enfermedad de Crohn que no responden adecuadament... | 2015-12-09 | due-trials |
| Reported results | 2010-023762-49 | A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE U... | 2013-04-22 | due-trials |
| Reported results | 2010-023782-22 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMAT... | 2014-06-09 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-023802-10 | AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELAT... | 2021-02-04 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-023873-20 | A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT rLP2086 VACCINE IN HEAL... | 2015-04-14 | bad-data |
| Reported results | 2010-024179-18 | A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER | 2012-05-25 | due-trials |
| Reported results | 2010-024181-22 | A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER... | 2012-11-19 | due-trials |
| Reported results | 2010-024219-15 | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH MODERATE TO S... | 2012-06-25 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-024638-48 | A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE (OPERA II) | 2016-07-27 | bad-data |
| Reported results | 2011-000420-15 | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2014-03-26 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000520-15 | A MULTICENTER, OPEN LABEL STUDY TO COMPARE ON DEMAND TREATMENT TO A PROPHYLAXIS REGIMEN OF NONACOG ALFA (BENEFIX) IN SUBJECTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤2%) | 2014-04-24 | bad-data |
| Reported results | 2011-000602-22 | A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-04991532 AND SITAGLIPTIN IN ADULT PATIENTS WIT... | 2012-03-15 | due-trials |
| Reported results | 2011-000722-30 | A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II) STUDIO DI ESTENSIONE MULTICENTRICO IN APERTO SUI SOGGETTI CHE HANNO PARTECIPATO ALLO STUDIO B0... | 2016-03-01 | due-trials |
| Reported results | 2011-000723-32 | A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-04991532 AND ONCE DAILY SITAGLIPTIN IN ADULT ... | 2012-03-27 | due-trials |
| Reported results | 2011-000903-41 | AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES | 2012-07-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-001412-65 | A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND A... | 2019-08-22 | bad-data |
| Reported results | 2011-001733-16 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN’... | 2015-03-17 | due-trials |
| Reported results | 2011-001754-28 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROH... | 2015-07-29 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-002008-33 | A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR | 2017-08-21 | bad-data |
| Reported results | 2011-002169-39 | A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS | 2019-05-20 | due-trials |
| Reported results | 2011-002190-33 | A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA | 2014-03-27 | due-trials |
| Reported results | 2011-002480-19 | A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-WAY CROSSOVER STUDY OF PREGABALIN IN THE TREATMENT OF FIBROMYALGIA WITH CONCURRENT ANTIDEPRESSANT THERAPY FOR COMORBID DEPRESSIO... | 2013-07-22 | due-trials |
| Reported results | 2011-002743-10 | A STUDY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY WITH BACKGROUND TREATMENT OF NSAID FOR OTHER PAIN CONDITIONS | 2013-11-22 | due-trials |
| Reported results | 2011-002896-40 | A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUN... | 2014-05-07 | due-trials |
| Reported results | 2011-003044-53 | AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER | 2012-12-10 | due-trials |
| Reported results | 2011-003062-32 | A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER | 2015-12-25 | due-trials |
| Reported results | 2011-003266-32 | A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSS-OVER EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY AND PAI... | 2013-07-02 | due-trials |
| Reported results | 2011-003622-27 | A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN?S DISEASE "Estudio de Extensión abierto de CP-690,550 como tratamiento de mantenimiento en pacientes con enf... | 2016-07-25 | due-trials |
| Reported results | 2011-003668-55 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paediatric i... | 2015-12-18 | due-trials |
| Reported results | 2011-004002-25 | A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND SITAGLIPTIN ON GLYCEMIC CONTROL IN ADULT PATIENTS WITH ... | 2013-01-24 | due-trials |
| Reported results | 2011-004363-74 | A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESEC... | 2018-07-26 | due-trials |
| Reported results | 2011-004400-38 | A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2... | 2020-03-17 | due-trials |
| Reported results | 2011-004578-27 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS Studio multice... | 2015-06-22 | due-trials |
| Reported results | 2011-004579-35 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | 2015-06-09 | due-trials |
| Reported results | 2011-004580-79 | A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS | 2016-05-27 | due-trials |
| Reported results | 2011-004581-14 | A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR... | 2020-08-06 | due-trials |
| Reported results | 2011-004914-40 | AN OPEN-LABEL MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CP-690,550 IN PEDIATRIC PATIENTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH JUVENILE IDIOPATHIC ARTHRITIS (... | 2015-12-04 | due-trials |
| Ongoing | 2011-004915-22 | A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) STUDIO DI FOLLOW-UP A LUNGO TERMINE, IN APERTO, SU CP-690,550 PER IL TRATTAMENTO DELL'ARTR... | not-yet-due | |
| Reported results | 2011-005206-30 | A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND GLIMEPIRIDE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELL... | 2013-01-28 | due-trials |
| Reported results | 2011-005448-87 | A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADE... | 2015-03-27 | due-trials |
| Reported results | 2011-005491-41 | An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (A... | 2017-01-04 | due-trials |
| Reported results | 2011-005513-37 | A PHASE 4, NON-TREATMENT FOLLOW-UP FOR CARDIAC ASSESSMENTS FOLLOWING USE OF SMOKING CESSATION TREATMENTS IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS | 2015-07-10 | due-trials |
| Reported results | 2011-005689-39 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) | 2015-03-18 | due-trials |
| Reported results | 2011-005697-31 | A DURATION OF IMMUNITY STUDY, TO ASSESS PERSISTENCE OF hSBA RESPONSE FOR UP TO 48 MONTHS AFTER COMPLETION OF VACCINATION WITH BIVALENT rLP2086 VACCINE | 2018-01-05 | due-trials |
| Reported results | 2011-005864-11 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH... | 2013-09-18 | due-trials |
| Exempt, with results | 2011-005875-17 | A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors | 2023-03-09 | not-yet-due |
| Reported results Terminated | 2011-005972-41 | A PHASE 4 MULTICENTER, OPEN-LABEL, PILOT STUDY OF PREGABALIN AND PREDICTION OF TREATMENT RESPONSE IN PATIENTS WITH POSTHERPETIC NEURALGIA. | 2013-06-12 | due-trials |
| Trial is outside EEC, and reported results | 2012-000482-21 | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS GIVEN WITH ROUTINE PEDIATRIC ... | bad-data | |
| Exempt, with results | 2012-000684-24 | A Phase 1B/2 Study To Evaluate The Safety And Efficacy of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose ARA-C Or Decitabine In Patients With Acute Myelo... | 2019-03-04 | not-yet-due |
| Trial is outside EEC, and reported results | 2012-000706-30 | An Open Label, Randomized, Single Dose, Two-Way Crossover bioequivalence Study Comparing a New 80 mg (2x40 mg) Pediatric Appropriate Formulation to an 80 mg Commercial Atorvastatin Calcium Tablet Form... | bad-data | |
| Trial is outside EEC, and reported results | 2012-000728-17 | An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing a Pediatric Appropriate Formulation to a 10 mg Commercial Atorvastatin Calcium Tablet Formulation in Healthy Su... | bad-data | |
| Reported results Terminated | 2012-000823-42 | A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO CONTROLLED, MULTI-DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RN6G (PF 04382923) IN SUBJECTS WIT... | 2013-04-10 | due-trials |
| Trial is outside EEC, and reported results | 2012-001133-14 | An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Children Aged 2 to <12 Years who are at Hi... | bad-data | |
| Trial is outside EEC, and reported results | 2012-001151-39 | An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Adolescents Aged 12 to <17 Years who are a... | bad-data | |
| Reported results | 2012-001226-10 | A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 FOLLOWING MONTHLY AND TWICE MONTHLY SUBCUTANE... | 2012-10-03 | due-trials |
| Reported results | 2012-002030-37 | A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TU... | 2016-02-04 | due-trials |
| Reported results | 2012-002031-28 | A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II) | 2017-12-13 | due-trials |
| Exempt, with results | 2012-002138-35 | A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer | 2019-02-12 | not-yet-due |
| Reported results | 2012-002465-35 | A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826) 20... | 2018-02-07 | due-trials |
| Reported results | 2012-002619-24 | A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HY... | 2020-09-28 | due-trials |
| Reported results | 2012-003197-57 | A MULTIPLE DOSE PHARMACOKINETIC OPEN-LABEL STUDY OF PREGABALIN (LYRICA) IN HEALTHY LACTATING WOMEN | 2013-08-16 | due-trials |
| Reported results | 2012-003223-38 | EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS | 2016-03-14 | due-trials |
| Reported results | 2012-003304-12 | A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain | 2015-08-04 | due-trials |
| Reported results | 2012-003332-23 | A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (... | 2014-09-22 | due-trials |
| Reported results | 2012-003593-51 | The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati... | 2023-02-06 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-003644-71 | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Etanercept in Subjects with Rheumatoid Arthritis Who Have Had and Inadequate Response to Adalimumab or Infliximab Plu... | bad-data | |
| Reported results | 2012-003721-22 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR ... | 2019-02-27 | due-trials |
| Exempt, with results | 2012-004104-35 | A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma | 2018-02-22 | not-yet-due |
| Reported results | 2012-004355-37 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING | 2014-10-17 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-004601-27 | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-... | 2023-11-20 | bad-data |
| Reported results | 2012-005495-34 | A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | 2018-12-20 | due-trials |
| Reported results | 2012-005645-20 | A PHASE 2B, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY, SAFETY, LOCAL TOLERABILITY AND PHARMACOKINETICS OF 2 DOSE STRENGTHS AND 2 REGIMENS OF TOFACI... | 2014-09-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-005665-12 | A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer | 2023-08-23 | bad-data |
| Completed, but no date, and reported results | 2012-005816-25 | A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2, 3, 4, 5 and 6 years after a booster dose of meningococcal serogroup A, C, W-135, Y- tetanus toxoi... | bad-data | |
| Reported results | 2013-000277-72 | The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Per... | 2022-08-23 | due-trials |
| Reported results | 2013-000691-15 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | 2020-06-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-000698-57 | A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer | 2024-01-10 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2013-000722-54 | A Phase 4, Randomized, Double Blind, Placebo Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer... | 2022-08-31 | bad-data |
| Reported results | 2013-001083-28 | A Phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2 doses of meningococcal conjugate vaccine MenACWY-TT in toddl... | 2019-12-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-001176-38 | A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma | 2024-04-18 | bad-data |
| Reported results | 2013-001352-34 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER | 2020-06-27 | due-trials |
| Reported results | 2013-001368-46 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE T... | 2016-04-04 | due-trials |
| Reported results Terminated | 2013-001426-26 | A phase 2, randomized, open label study to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics of the anti-ALK-1 MAB PF-03446962 in combination with best supportive care vs. best support... | 2014-06-26 | due-trials |
| Reported results | 2013-001549-15 | The long-term antibody persistence of MenACWY-TT vaccine (PF-06866681) versus Meningitec® or Mencevax® ACWY in healthy adolescents and adults and a booster dose of MenACWY-TT administered 10 years pos... | 2018-06-11 | due-trials |
| Reported results | 2013-001557-27 | A PHASE 2, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIALTO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL AMYL... | 2015-09-23 | due-trials |
| Exempt, with results | 2013-001986-18 | A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer | 2016-01-25 | not-yet-due |
| Reported results | 2013-002095-40 | A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER | 2016-04-06 | due-trials |
| Exempt, with results | 2013-002096-18 | AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5-FLUOROURACIL-LEUCOVORIN-IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER | 2015-08-05 | not-yet-due |
| Trial is outside EEC, and reported results | 2013-002137-38 | A Phase 2, Randomized, ACTIVE-CONTROLLED, observer-blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil® (HPV) Vaccine and BIVALENT RLP2086 Vaccine When Administered Conco... | bad-data | |
| Trial is outside EEC, and reported results | 2013-002145-11 | A Phase 2, Randomized, Active-controlled, observer-blindED Trial, to Assess the Safety, Tolerability, and Immunogenicity of MCV4, TDAP Vaccine and bivalent RLP2086 Vaccine When Administered Concomitan... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2013-002223-42 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAI... | 2021-06-25 | bad-data |
| Reported results | 2013-002549-12 | A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT | 2019-07-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-002580-26 | Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (FASLODEX) with or without PD-0332991 (PALBOCICLIB) ± Goserelin in Women with Hormone Receptor-Positive, Her2-Ne... | 2022-09-28 | bad-data |
| Exempt, with results | 2013-002620-17 | Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations. | 2023-06-28 | not-yet-due |
| Reported results | 2013-002642-37 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMI... | 2016-04-05 | due-trials |
| Reported results | 2013-002643-28 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED D... | 2016-07-05 | due-trials |
| Reported results | 2013-002644-87 | A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTE... | 2016-05-06 | due-trials |
| Reported results | 2013-002646-36 | PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB(PF-04950615), IN REDUCING THE OCCURRENCE OF MAJO... | 2017-03-22 | due-trials |
| Reported results | 2013-002716-28 | A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Wh... | 2021-03-05 | due-trials |
| Ongoing, reported early | 2013-002717-35 | A Phase 2, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estroge... | not-yet-due | |
| Reported results | 2013-002795-41 | PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJO... | 2017-04-03 | due-trials |
| Reported results | 2013-003076-12 | A Phase 2, 2-Stage. 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Estudio de fase 2, de 2 etapas y 2 cohortes, en e... | 2018-10-31 | due-trials |
| Reported results | 2013-003147-27 | A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF RAN... | 2015-08-11 | due-trials |
| Reported results | 2013-003177-99 | PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS | 2020-12-31 | due-trials |
| Reported results | 2013-003250-25 | A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors | 2020-10-13 | due-trials |
| Reported results | 2013-003420-37 | A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 1 MONTH THROUGH <4 YEARS OF AGE WITH PARTIAL ONSET SEIZ... | 2018-03-13 | due-trials |
| Completed, but no date, and reported results | 2013-004090-28 | TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS) – OPTIONAL BLOOD SAMPLE COLLECTION SUBSTUDY Sondaggio Sugli Esiti dell’Amiloidosi da Transtiretina (Transthyretin-Associated Amyloidosis... | bad-data | |
| Reported results | 2013-004148-49 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTH... | 2017-06-01 | due-trials |
| Reported results | 2013-004362-34 | A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) | 2021-02-26 | due-trials |
| Reported results | 2013-004508-21 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE H... | 2018-11-14 | due-trials |
| Reported results | 2013-004552-38 | A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W... | 2023-01-13 | due-trials |
| Reported results | 2013-004569-16 | A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis | 2016-06-18 | due-trials |
| Reported results | 2013-004679-11 | A Randomized, Double-blind Pharmacokinetic Study of PF-05280014 Plus Taxotere and Carboplatin Versus Herceptin Plus Taxotere And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable HER... | 2016-03-09 | due-trials |
| Reported results | 2013-005101-31 | A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | 2020-04-17 | due-trials |
| Reported results | 2014-000132-41 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA | 2018-05-18 | due-trials |
| Reported results | 2014-000352-29 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTH... | 2017-12-06 | due-trials |
| Reported results | 2014-000358-13 | A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ... | 2016-12-16 | due-trials |
| Reported results | 2014-000478-20 | A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYS... | 2016-07-14 | due-trials |
| Reported results | 2014-000706-34 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (CP-6... | 2015-07-06 | due-trials |
| Reported results Terminated | 2014-000830-42 | A Randomized, 18-Week, Placebo Controlled, Double Blind, Parallel Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Ne... | 2015-10-23 | due-trials |
| Reported results | 2014-000933-21 | A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCINE (... | 2017-03-01 | due-trials |
| Reported results | 2014-001048-40 | A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | 2018-01-31 | due-trials |
| Reported results | 2014-001051-23 | A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma | 2017-09-12 | due-trials |
| Reported results | 2014-001052-39 | The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Singl... | 2015-08-14 | due-trials |
| Trial is outside EEC, and reported results | 2014-001174-34 | A PHASE 4/3, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 50 TO 65 YEARS OF AGE AND IN CHILDREN 6 TO 17 YEA... | bad-data | |
| Reported results | 2014-001291-56 | A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | 2016-10-04 | due-trials |
| Ongoing | 2014-001634-28 | A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing ... | not-yet-due | |
| Reported results Terminated | 2014-002072-92 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 In Ambulatory Boys With Duc... | 2018-11-30 | due-trials |
| Not reported | 2014-002182-29 | An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Wh... | 2023-02-04 | due-trials |
| Reported results | 2014-002286-30 | PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS | 2016-01-26 | due-trials |
| Reported results Terminated | 2014-002340-40 | A Randomized, Double-Blind, Placebo-Controlled 2-Way Crossover Study to Evaluate the Efficacy, Safety and Tolerability of PF-03715455 Administered Twice Daily By Inhalation for 4 Weeks in Subjects wit... | 2015-03-27 | due-trials |
| Reported results | 2014-002644-40 | A PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4- ANTIGEN VACCINE (SA4Ag) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPIN... | 2019-07-26 | due-trials |
| Exempt, with results | 2014-002826-11 | A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutatio... | 2017-07-10 | not-yet-due |
| Reported results | 2014-003242-28 | A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronida... | 2017-06-01 | due-trials |
| Reported results | 2014-003243-34 | Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis | 2017-12-30 | due-trials |
| Reported results | 2014-003244-13 | A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from ... | 2017-09-15 | due-trials |
| Trial is outside EEC, and reported results | 2014-003737-26 | A Phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluate the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in paediatric subjects with juvenile idi... | bad-data | |
| Reported results | 2014-003822-42 | A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years. | 2016-01-20 | due-trials |
| Reported results | 2014-003878-16 | A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-... | 2017-12-22 | due-trials |
| Trial is outside EEC, and reported results | 2014-004101-33 | A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients | bad-data | |
| Trial is outside EEC, and reported results | 2014-004102-15 | An open label comparative study of de novo renal allograft recipients receiving CsA + MMF + corticosteroids versus CsA + Rapamune + corticosteroids with further CsA elimination in the Rapamune arm wi... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004103-73 | A long-term, open-label study of TNR-001 in Japanese Juvenile Idiopathic Arthritis Subjects. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004105-32 | Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid Ther... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004106-15 | An Evaluation of the Safety and Efficacy of On-Demand Treatment with Xyntha (B-Domain Deleted Recombinant Factor VIII, Albumin Free) in Chinese Subjects with Hemophilia A | bad-data | |
| Trial is outside EEC, and reported results | 2014-004155-32 | An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX ) in Children Less Than 6 Years of Age With Severe Hemophilia B | bad-data | |
| Trial is outside EEC, and reported results | 2014-004156-65 | An Evaluation of the Safety and Efficacy of On-Demand Treatment with BeneFIX (Nonacog Alfa, Recombinant Factor IX) in Chinese Subjects with Hemophilia B | bad-data | |
| Trial is outside EEC, and reported results | 2014-004158-32 | PILOT: Characterization of the Prevnar Infant Long-Term Immune Response Versus a Prevnar-Naïve Cohort | bad-data | |
| Trial is outside EEC, and reported results | 2014-004161-24 | An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years | bad-data | |
| Trial is outside EEC, and reported results | 2014-004162-17 | A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD) | bad-data | |
| Trial is outside EEC, and reported results | 2014-004163-21 | Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa | bad-data | |
| Trial is outside EEC, and reported results | 2014-004164-38 | An Open Label, Randomized, Single Dose, Parallel Arm Study To Determine Pharmacokinetics Of Azithromycin Following Oral Administration Of Immediate-Release (IR) Or Extended-Release (ER) Formulation In... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004166-23 | A 7-Day, Open-Label, Multicenter, Pharmacokinetic (PK) Study (Part 1) Followed by A 7-Day, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study (Part 2) of Int... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004167-20 | A Phase 3, Multi-Center, Open-Label Study To Confirm Safety, Efficacy And Tolerability Of Sildenafil Citrate 20 Mg Three Times a Day (TID) In Subjects With Pulmonary Arterial Hypertension | bad-data | |
| Trial is outside EEC, and reported results | 2014-004172-32 | A Four-Year Open-Label Multi-Center Randomized Two-Arm Study of Genotropin in Idiopathic Short Stature Subjects: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of Geno... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004173-16 | A Multicenter, Open-Label, Single Arm Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Pen | bad-data | |
| Trial is outside EEC, and reported results | 2014-004174-42 | An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Subjects With Partial Seizures When Other Antiepileptics Do Not ... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004175-23 | A 52 weeks, open-label, multicenter study evaluating the efficacy and safety of gabapentin as adjunctive therapy in pediatric subjects who have completed the 12 weeks treatment in study A9451162. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004176-35 | Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I | bad-data | |
| Trial is outside EEC, and reported results | 2014-004177-16 | A Phase 4, Randomized, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan. | bad-data | |
| Trial is outside EEC, and reported results | 2014-004178-40 | A Phase 4, Open-label Trial to Assess the Safety, Tolerability, and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination | bad-data | |
| Trial is outside EEC, and reported results | 2014-004179-22 | A Study To Evaluate Pneumococcal Antipolysaccharide Antibody Concentrations in Subjects That Participated in the Wyeth Prevenar Safety and Immunogenicity Study 0887X-101518 | bad-data | |
| Trial is outside EEC, and reported results | 2014-004180-20 | A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants | bad-data | |
| Trial is outside EEC, and reported results | 2014-004181-21 | A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-Labe... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004183-38 | An open, intravenous multiple dose, multi-centre study to investigate the pharmacokinetics, safety and toleration of Voriconazole in children aged 2-12 years who require treatment for the prevention o... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004184-21 | An open-label, intravenous to oral switch, multiple dose, multi-centre study to investigate the pharmacokinetics, safety and tolerability of Voriconazole in hospitalized children aged 2 to <12 years w... | bad-data | |
| Reported results Terminated | 2014-004900-31 | AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021 | 2017-02-06 | due-trials |
| Trial is outside EEC, and reported results | 2014-004906-14 | An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithromyc... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004952-80 | Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Malaria... | bad-data | |
| Trial is outside EEC, and reported results | 2014-004953-14 | A Phase 3, Randomized, Active-Controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 7-Valent Pneumococcal Conjugate Vac... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2015-000515-41 | A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTA... | 2022-09-02 | bad-data |
| Reported results | 2015-000541-24 | A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response | 2019-09-06 | due-trials |
| Trial is outside EEC, and reported results | 2015-000606-20 | Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disord... | bad-data | |
| Trial is outside EEC, and reported results | 2015-000607-15 | 26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) | bad-data | |
| Reported results | 2015-001438-46 | EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS | 2019-05-16 | due-trials |
| Trial is outside EEC, and reported results | 2015-001874-16 | Placebo Controlled, Double Blind Evaluation of the Efficacy and Safety of Ibuprofen 5% Topical Gel for the Treatment of Ankle Sprain | bad-data | |
| Exempt, with results | 2015-001879-43 | A Phase 1b/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Either Crizotinib or PF-06463922 in Patie... | 2022-07-13 | not-yet-due |
| Trial is outside EEC, and reported results | 2015-002238-37 | A Local, Multicentre, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Trea... | bad-data | |
| Listed as ongoing, but also has a completion date | 2015-002429-20 | A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) ) MONOTHERAPY IN THE FIRST-LINE TREATM... | 2024-06-26 | bad-data |
| Exempt, with results | 2015-002552-27 | A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ... | 2023-03-23 | not-yet-due |
| Reported results | 2015-002726-39 | A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abdomi... | 2017-10-26 | due-trials |
| Trial is outside EEC, and reported results | 2015-003027-61 | An open-label, single dose pharmacokinetic study of BeneFIX (nonacog alfa, recombinant factor IX) in male Chinese subjects with haemophilia B. | bad-data | |
| Reported results | 2015-003091-77 | A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone to In Patients... | 2022-07-12 | due-trials |
| Reported results | 2015-003239-36 | A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untrea... | 2019-05-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003262-86 | A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PA... | 2023-04-26 | bad-data |
| Trial is outside EEC, and reported results | 2015-003685-88 | An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (moroctocog Alfa (af-cc), Recombinant Factor VIII) In Male Chinese Subjects With Hemophilia A | bad-data | |
| Trial is outside EEC, and reported results | 2015-004552-21 | Long-term study of PNU-180307 for short children born small for gestational age (SGA) without epiphyseal closure (extension of the study 307-MET-0021-002) | bad-data | |
| Reported results Terminated | 2015-004912-39 | A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARK... | 2017-11-10 | due-trials |
| Trial is outside EEC, and reported results | 2015-005040-33 | An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (moroctocog-alfa (af-cc), Recombinant FVIII) In Subjects With Hemophilia A In Usual Care Se... | bad-data | |
| Reported results | 2015-005513-72 | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPI... | 2017-04-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-005805-35 | A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotec... | 2022-11-10 | bad-data |
| Reported results | 2016-000394-21 | A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES. | 2018-03-20 | due-trials |
| Trial is outside EEC, and reported results | 2016-000765-22 | An Open-label, Single-arm, Post-authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Benefix (nonacog Alfa, Recombinant Factor IX) In Subjects With Hemophilia B In Usual Care Settings ... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000868-42 | A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61MG] IN SUBJECTS DIAGNOSED W... | 2023-11-23 | bad-data |
| Trial is outside EEC, and reported results | 2016-001119-19 | Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis | bad-data | |
| Reported results | 2016-001158-16 | A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN-LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLI... | 2018-08-22 | due-trials |
| Reported results | 2016-001456-21 | A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN TH... | 2020-06-19 | due-trials |
| Reported results | 2016-001575-71 | A 15 WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON’S DISEA... | 2018-01-29 | due-trials |
| Reported results | 2016-001615-21 | A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy | 2018-11-22 | due-trials |
| Reported results | 2016-001825-15 | A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATIO... | 2018-12-17 | due-trials |
| Exempt, with results | 2016-001885-27 | A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJEC... | 2018-12-03 | not-yet-due |
| Reported results | 2016-001972-31 | A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib | 2021-07-22 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002036-32 | A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy an... | 2023-03-01 | bad-data |
| Reported results | 2016-002337-30 | A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEU... | 2018-08-15 | due-trials |
| Reported results | 2016-002862-30 | A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06651600 IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMAT... | 2017-12-12 | due-trials |
| Exempt, with results | 2016-002904-15 | PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS ... | 2019-12-02 | not-yet-due |
| Ongoing | 2016-003315-35 | A PHASE 3, RANDOMIZED, OPEN LABEL STUDY OF LORLATINIB (PF 06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED ALK POSITIVE NON SMALL CELL LUNG CAN... | not-yet-due | |
| Reported results | 2016-003708-29 | A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ul... | 2021-05-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-003866-14 | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 2022-02-11 | bad-data |
| Trial is outside EEC, and reported results | 2016-003978-41 | A Phase 3, Multi-center, Open label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension | bad-data | |
| Reported results | 2016-004421-17 | A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN S... | 2022-10-25 | due-trials |
| Trial is outside EEC, and reported results | 2016-005134-29 | A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13- VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS WHEN GIVEN WITH ROUTINE PEDI... | bad-data | |
| Trial is outside EEC, and reported results | 2017-000125-13 | A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus | bad-data | |
| Reported results Terminated | 2017-000128-81 | PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE | 2017-10-24 | due-trials |
| Trial is outside EEC, and reported results | 2017-000197-11 | Post Marketing Surveillance Study To Evaluate The Safety And Efficacy Of Vfend® IV | bad-data | |
| Trial is outside EEC, and reported results | 2017-000307-24 | AN OPEN LABEL NON-RANDOMIZED STUDY TO CHARACTERIZE THE STEADY STATE PHARMACOKINETICS OF SULFASALAZINE DELAYED RELEASE TABLETS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS | bad-data | |
| Trial is outside EEC, and reported results | 2017-000501-20 | Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-comparative Study | bad-data | |
| Reported results | 2017-001156-55 | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-Weeks To Ad... | 2019-03-26 | due-trials |
| Reported results | 2017-001255-31 | A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA | 2020-08-05 | due-trials |
| Ongoing | 2017-001271-23 | AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR FACTOR VIII (FVIII) PROPHYLAXIS REPLACEM... | not-yet-due | |
| Exempt, with results | 2017-001509-33 | A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOC... | 2023-01-04 | not-yet-due |
| Trial is outside EEC, and reported results | 2017-001529-41 | Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination | bad-data | |
| Exempt, with results | 2017-001741-27 | A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE T... | 2022-12-20 | not-yet-due |
| Completed, reported early | 2017-002018-29 | EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS | 2024-03-27 | not-yet-due |
| Reported results | 2017-002108-28 | A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE C... | 2021-01-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-002274-39 | A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION | 2022-03-18 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-002742-68 | A Phase 3 Prospective, Randomized, Multicenter, Open-Label, Central Assessor-Blinded, Parallel Group, Comparative Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-A... | 2023-02-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-002822-19 | A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PAT... | 2022-12-30 | bad-data |
| Other | 2017-003295-31 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer | not-yet-due | |
| Completed, reported early | 2017-003359-43 | A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF- 06700841 As Induction And Open Label Extension Treatment ... | 2023-12-13 | not-yet-due |
| Exempt, with results | 2017-003464-12 | An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorec... | 2021-02-25 | not-yet-due |
| Reported results | 2017-003651-29 | A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with mode... | 2019-03-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-004310-25 | A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation | 2022-10-13 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004345-24 | A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO) IN COMBINATION WITH AXITINIB (INLYTA) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL C... | 2023-02-09 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004456-30 | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH TH... | 2021-12-22 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004544-38 | A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECT... | 2023-01-23 | bad-data |
| Listed as ongoing, but also has a completion date | 2017-004851-22 | A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod... | 2024-04-17 | bad-data |
| Exempt, with results | 2018-000124-34 | A Phase 1b/2, study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-Mutant Solid Tu... | 2021-02-02 | not-yet-due |
| Reported results | 2018-000226-58 | A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS) | 2020-08-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-000345-39 | A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors | 2023-02-03 | bad-data |
| Reported results | 2018-000501-23 | A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe ... | 2020-10-07 | due-trials |
| Trial is outside EEC, and reported results | 2018-000731-27 | A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Of The Safety And Efficacy Of AN2728 Topical Ointment, 2% In Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic De... | bad-data | |
| Trial is outside EEC, and reported results | 2018-000761-37 | A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adoles... | bad-data | |
| Trial is outside EEC, and reported results | 2018-000904-40 | A Multicenter, Open-Label Study Of The Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-000918-38 | A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN®... | 2020-08-28 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001043-31 | A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLER... | 2020-12-11 | bad-data |
| Reported results | 2018-001136-21 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Mode... | 2019-08-13 | due-trials |
| Reported results | 2018-001271-20 | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUAT... | 2021-03-05 | due-trials |
| Trial is outside EEC, and reported results | 2018-001321-68 | Gemtuzumab Ozogamicin (mylotarg (registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/refractory Acute Myelogenous Leukemia Who May Benefit From Treatment... | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001557-27 | A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL ... | 2023-05-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001714-14 | A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GR... | 2021-06-24 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-001946-32 | A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018 Multicentrická... | 2022-10-05 | bad-data |
| Ongoing | 2018-002378-30 | OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | not-yet-due | |
| Reported results | 2018-002573-21 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO I... | 2020-03-06 | due-trials |
| Reported results | 2018-002588-24 | A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA® WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE | 2023-09-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002619-89 | A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33... | 2021-07-22 | bad-data |
| Reported results | 2018-002800-16 | A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS F... | 2022-11-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002841-12 | A Phase 1, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety And Tolerability Of Ceftazidime-Avibactam (Caz-Avi) In Children From 3 Months To Less Than 18 Years Of Age Who Are Hospi... | 2021-09-26 | bad-data |
| Reported results | 2018-003050-24 | A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWIC... | 2020-05-07 | due-trials |
| Reported results | 2018-003051-38 | A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR ... | 2021-04-20 | due-trials |
| Trial is outside EEC, and reported results | 2018-003054-24 | A Phase 3, Multicenter, Single-arm, Open-label Study To Assess The Safety, Tolerability, And Immunogenicity Of A Single Dose Of 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To ... | bad-data | |
| Other | 2018-003086-33 | Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemop... | not-yet-due | |
| Reported results Terminated | 2018-003612-45 | TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE) | 2020-12-14 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-003660-31 | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coag... | 2021-09-10 | bad-data |
| Reported results | 2018-003804-37 | A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT... | 2020-04-08 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-003987-29 | An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis | 2023-06-30 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-004175-12 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMA... | 2023-10-05 | bad-data |
| Reported results | 2018-004241-16 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATI... | 2021-01-15 | due-trials |
| Reported results | 2018-004278-91 | A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ?65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | 2020-02-12 | due-trials |
| Reported results | 2018-004279-11 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE–NAÏVE ADULTS 18 YEARS OF AGE AND OLDER | 2019-12-09 | due-trials |
| Reported results | 2018-004555-21 | A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis | 2022-01-27 | due-trials |
| Reported results | 2018-004669-16 | A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | 2020-11-26 | due-trials |
| Reported results | 2019-000218-12 | A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MEL... | 2021-07-07 | due-trials |
| Reported results | 2019-000284-24 | A RANDOMIZED COMPARATIVE STUDY ASSESSING THE INTERCHANGEABILITY OF PF-06410293 AND HUMIRA® IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS. | 2021-06-22 | due-trials |
| Other | 2019-000417-37 | A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer | not-yet-due | |
| Completed, but no date, and reported results | 2019-000443-28 | A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks i... | bad-data | |
| Trial is outside EEC, and reported results | 2019-000890-21 | A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA | bad-data | |
| Trial is outside EEC, and reported results | 2019-000926-23 | A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCI... | bad-data | |
| Ongoing | 2019-001084-71 | A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA | not-yet-due | |
| Exempt, with results | 2019-001358-24 | A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Advanc... | 2020-09-29 | not-yet-due |
| Completed, but no date, and reported results Terminated | 2019-001386-33 | A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients with Invasive Mold Infections Caused by Aspergillus Species or Rare Molds | bad-data | |
| Trial is outside EEC, and reported results | 2019-001552-18 | A LOCAL, SINGLE-CENTRE, EXTENSION, OPEN LABEL ACCESS STUDY, TO PROVIDE SILDENAFIL THERAPY FOR SUBJECTS WHO COMPLETED A1481156 STUDY AND ARE JUDGED BY THE INVESTIGATOR TO DERIVE CLINICAL BENEFIT FROM C... | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-002504-41 | Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine... | 2024-10-23 | bad-data |
| Reported results | 2019-002676-14 | A 24-WEEK RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF 06650833, PF-06651600 (RITLECITINIB) AND TOFACITINIB ALONE AND IN COMBI... | 2022-02-07 | due-trials |
| Listed as ongoing, but also has a completion date | 2019-002698-74 | A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SE... | 2022-10-25 | bad-data |
| Trial is outside EEC, and reported results | 2019-002836-10 | A Phase 4, Multicenter, Open Label Safety Study Of Crisaborole Ointment 2% In Children Aged 3 Months To Less Than 24 Months With Mild To Moderate Atopic Dermatitis | bad-data | |
| Other | 2019-002921-31 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | not-yet-due | |
| Reported results | 2019-002943-85 | A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINAT... | 2023-10-27 | due-trials |
| Trial is outside EEC, and reported results | 2019-003305-10 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | bad-data | |
| Reported results | 2019-003306-27 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFA... | 2023-02-18 | due-trials |
| Reported results | 2019-003307-35 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | 2022-08-31 | due-trials |
| Trial is outside EEC, and reported results | 2019-003308-11 | A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE | bad-data | |
| Ongoing | 2019-003375-19 | A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 antibody, in Combination With Bacillus Calmette- Guerin (BCG Induction With or Without BCG Maint... | not-yet-due | |
| Reported results | 2019-003607-35 | A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOC... | 2023-02-14 | due-trials |
| Reported results Terminated | 2019-003999-39 | A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE U... | 2020-09-24 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-004013-13 | A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOP... | 2021-07-23 | bad-data |
| Reported results | 2019-004313-13 | A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE | 2022-07-24 | due-trials |
| Ongoing | 2019-004451-37 | Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe... | not-yet-due | |
| Completed, report not yet due | 2019-004775-39 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTE... | 2024-02-21 | not-yet-due |
| Trial is outside EEC, and reported results | 2020-000875-20 | A Phase 2b, Multi Center, Randomized, Double-Blind, Vehicle-Controlled, Intra-Participant Study, to Evaluate Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Pediatric and Ad... | bad-data | |
| Reported results Terminated | 2020-000948-60 | A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE | 2022-09-15 | due-trials |
| Reported results Terminated | 2020-001189-13 | A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA | 2023-03-27 | due-trials |
| Other | 2020-001288-99 | AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETU... | not-yet-due | |
| Completed, reported early | 2020-001509-21 | A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA | 2024-05-07 | not-yet-due |
| Ongoing | 2020-001757-40 | PHASE 1/2a DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF 06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOC... | not-yet-due | |
| Other | 2020-002443-38 | Phase 3 open-label study to evaluate efficacy, safety, and tolerability of FIX gene transfer with fidanacogene elaparvovec (PF-06838435) in pediatric male participants <18 years of age with moderately... | not-yet-due | |
| Reported results | 2020-002782-34 | A phase 1, open-label, randomized, 2-period, 2 sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants un... | 2021-01-15 | due-trials |
| Reported results | 2020-002796-35 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participants ... | 2021-12-06 | due-trials |
| Exempt | 2020-002829-28 | A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC) | 2024-10-29 | not-yet-due |
| Trial is outside EEC, and reported results | 2020-003216-28 | A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP PILOT STUDY TO EVALUATE THE EFFICACY OF DEXTROMETHORPHAN HYDROBROMIDE ON ACUTE COUGH IN A PEDIATRIC POPULATION | bad-data | |
| Reported results | 2020-003226-23 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis | 2023-06-30 | due-trials |
| Trial is outside EEC, and reported results | 2020-003373-21 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | bad-data | |
| Other | 2020-003517-35 | Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children ... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2020-003610-12 | ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | 2024-09-02 | bad-data |
| Other | 2020-003761-18 | Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-003972-42 | A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR... | bad-data | |
| Reported results | 2020-003977-23 | A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 6 WEEKS IN PARTICIPANTS WIT... | 2021-08-18 | due-trials |
| Trial is outside EEC, and reported results | 2020-004088-26 | 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC) | bad-data | |
| Trial is outside EEC, and reported results | 2020-004192-41 | LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY OF FESOTERODINE IN JAPANESE PEDIATRIC SUBJECTS WITH SYMPTOMS OF DETRUSOR OVERACTIVITY ASSOCIATED WITH A NEUROLOGICAL CONDITION (NEUROGENIC DETRUSOR OVE... | bad-data | |
| Reported results | 2020-004228-41 | A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS | 2022-11-28 | due-trials |
| Trial is outside EEC, and reported results | 2020-004430-38 | A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH NONACOG ALFA PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATELY-SEVERE TO SE... | bad-data | |
| Other | 2020-004533-21 | AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF PF-06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY ... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-004570-21 | A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH MOROCTOCOG ALFA (AF-CC) PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATE AND... | bad-data | |
| Ongoing | 2020-004850-31 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECT... | not-yet-due | |
| Ongoing | 2020-005030-15 | AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEA... | not-yet-due | |
| Trial is outside EEC, and reported results | 2020-005039-59 | A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCI... | bad-data | |
| Reported results | 2020-005059-19 | A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE BADANIE FAZY 3B PROWADZONE METODĄ OTWARTEJ PRÓBY OCENIAJĄC... | 2022-09-09 | due-trials |
| Other | 2021-000044-22 | AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOM... | not-yet-due | |
| Other | 2021-000248-23 | TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | not-yet-due | |
| Ongoing | 2021-000803-20 | An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Lenalidomide + Dexamethas... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-001266-38 | A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS | bad-data | |
| Trial is outside EEC, and reported results | 2021-002155-11 | A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ACCESS THE EFFICACY AND SAFETY OF PF-06462700 ADMINISTERED INTRAVENOUSLY AT 40 MG/KG/DAY FOR 4 DAYS IN JAPANESE PARTICIPANTS WITH MODERATE AND ABOVE APLA... | bad-data | |
| Other | 2021-002457-29 | AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES | not-yet-due | |
| Reported results | 2021-002857-28 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIP... | 2022-07-25 | due-trials |
| Reported results | 2021-002894-24 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATIC S... | 2022-04-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2021-002895-38 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIP... | 2022-04-22 | bad-data |
| Other | 2021-002897-19 | AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA BEAVA... | not-yet-due | |
| Reported results | 2021-003149-39 | A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA | 2023-04-30 | due-trials |
| Ongoing | 2021-003444-25 | PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE® ) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR RE... | not-yet-due | |
| Other | 2021-003640-24 | A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DU... | not-yet-due | |
| Ongoing | 2021-003693-31 | A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS | not-yet-due | |
| Not reported Terminated | 2021-003702-42 | AN INTERVENTIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY... | 2022-11-11 | due-trials |
| Other | 2021-003715-26 | A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC CO... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-003805-23 | A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS | bad-data | |
| Other | 2021-004395-34 | ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2021-004787-10 | AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS. | 2023-11-20 | bad-data |
| Ongoing | 2021-005239-22 | A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens | not-yet-due | |
| Other | 2021-005246-15 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of age Studio di ... | not-yet-due | |
| Ongoing | 2021-005427-20 | A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISEASE... | not-yet-due | |
| Other | 2021-005569-42 | LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZ... | not-yet-due | |
| Other | 2021-006010-37 | CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES PROTOCOLLO PRINCIPALE DI CRIZOTINIB: STUDIO DI PROSECUZION... | not-yet-due | |
| Other | 2021-006052-14 | A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autolog... | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-006538-38 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CRISABOROLE OINTMENT, 2% IN CHINESE AND JAPANESE PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND... | bad-data | |
| Reported results | 2021-006624-41 | A PHASE 3, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY TODDLERS 12 THROUGH 23 MONTHS OF AGE WITH 2 PRIOR I... | 2023-06-01 | due-trials |
| Other | 2022-000075-39 | A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZE... | not-yet-due | |
| Other | 2022-000186-40 | A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PR... | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-000845-34 | A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHILDREN AGED 5 MONTHS TO ≤60 MONTHS AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS | bad-data | |
| Trial is outside EEC, and reported results | 2022-001146-38 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS | bad-data | |
| Other | 2022-001175-14 | BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | not-yet-due | |
| Other | 2022-001176-34 | BHV3000-407: A Phase 4, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2022-001362-35 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC CO... | 2023-11-13 | bad-data |
| Other | 2022-001679-15 | PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION ... | not-yet-due | |
| Other | 2022-001809-50 | A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROM... | not-yet-due | |
| Other | 2022-002173-28 | PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINA... | not-yet-due | |
| Not reported | 2022-002447-22 | AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID-19... | 2023-02-01 | due-trials |
| Completed, reported early | 2022-002827-36 | AN INTERVENTIONAL, EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE A REPEAT 5-DAY COURSE OF NIRMATRELVIR/RITONAVIR COMPARED TO PLACEBO/RITONAVIR IN PARTICIPANTS AT L... | 2024-02-09 | not-yet-due |
| Reported results Terminated | 2022-002834-15 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH ... | 2023-09-22 | due-trials |
| Ongoing | 2022-003016-87 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-... | not-yet-due | |
| Completed, report not yet due | 2022-003361-37 | A PHASE 2/3, TWO-PART STUDY TO EVALUATE THE EFFICACY AND LONG-TERM SAFETY WITH ORAL ETRASIMOD, 2 MG, ONCE DAILY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS WITH A HISTORY OF PRIOR ... | 2024-04-29 | not-yet-due |
| Trial is outside EEC, and reported results | 2022-004181-37 | A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER | bad-data | |
| Trial is outside EEC, and reported results | 2023-000824-12 | AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA | bad-data | |
| Trial is outside EEC, and reported results | 2024-000101-32 | A PHASE 3 MULTICENTER, OPEN LABEL, MULTI COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SOMATROPIN IN JAPANESE PARTICIPANTS WITH PRADER-WILLI SYNDROME (PWS) | bad-data | |
| Trial is outside EEC, and reported results | 2024-000141-26 | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABROCITINIB 100 MG AND 200 MG TABLETS IN PARTICIPANTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMA... | bad-data | |
| Trial is outside EEC, and reported results | 2024-000422-17 | A PHASE 1, OPEN-LABEL, AGE DESCENDING, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE (RSVpreF) IN CHILDREN 2 T... | bad-data | |
| Trial is outside EEC, and reported results | 2024-000442-10 | CRIZOTINIB (XALKORI(REGISTERED)) EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADULT OR PEDIATRIC PATIENTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES THAT HARBOR A CRIZOTINIB-SENSITIVE MOLECULAR ALTERATIO... | bad-data |